Cynosure (CYNO) Inactive 10-K13 Mar 152014 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2014	Mar. 09, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	CYNO
Entity Registrant Name	CYNOSURE INC
Entity Central Index Key	885306
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		21,732,279
Entity Public Float			$464,892,455

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$75,131	$93,655
Short-term marketable securities	32,055	26,633
Accounts receivable, net of allowance of $2,949 and $1,803 in 2014 and 2013, respectively	42,524	36,587
Inventories	59,318	50,251
Prepaid expenses and other current assets	9,629	6,891
Deferred income taxes	17,228	9,341
Total current assets	235,885	223,358
Property and equipment, net	34,256	26,445
Long-term marketable securities	26,189	8,804
Goodwill	105,764	99,237
Intangibles, net	53,583	55,179
Other assets	2,047	1,678
Total assets	457,724	414,701
Current liabilities:
Accounts payable	20,856	13,985
Amounts due to related party		1,268
Accrued expenses	42,426	36,954
Deferred revenue	10,971	9,163
Current portion of capital lease obligations	137	286
Total current liabilities	74,390	61,656
Capital lease obligations, net of current portion	16,088	14,957
Deferred revenue, net of current portion	809	1,010
Other noncurrent liabilities	8,325	8,726
Commitments and Contingencies (Note 13)
Stockholders' equity:
Preferred stock, $0.001 par value Authorized-5,000 shares as of December 31, 2014 and 2013 Issued-no shares as of December 31, 2014 and 2013
Class A and Class B common stock, $0.001 par value Authorized-70,000 shares as of December 31, 2014 and 2013 Issued-23,253 Class A shares and no Class B shares at December 31, 2014 Issued-22,633 Class A shares and no Class B shares at December 31, 2013	23	23
Additional paid-in capital	355,082	338,742
Retained earnings	39,974	8,636
Accumulated other comprehensive loss	-3,863	-1,499
Treasury stock, 1,628 Class A shares, at cost, at December 31, 2014; 886 Class A shares, at cost, at December 31, 2013	-33,104	-17,550
Total stockholders' equity	358,112	328,352
Total liabilities and stockholders' equity	$457,724	$414,701

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Allowance for doubtful accounts receivable	$2,949	$1,803
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Class A and Class B common stock, shares authorized	70,000,000	70,000,000
Common stock, par value	$0.00
Common Stock Class A [Member]
Class A and Class B common stock, shares authorized	61,500,000
Common stock, par value	$0.00	$0.00
Common stock, shares issued	23,253,000	22,633,000
Treasury stock, shares	1,628,000	886,000
Common Stock Class B [Member]
Class A and Class B common stock, shares authorized	8,500,000
Common stock, par value	$0.00	$0.00
Common stock, shares issued	0	0

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
Product revenues	$236,878	$188,271	$128,513
Parts, accessories, service and royalty revenues	55,491	37,739	24,980
Total revenues	292,369	226,010	153,493
Cost of revenues	127,131	95,730	64,567
Gross profit	165,238	130,280	88,926
Operating expenses:
Sales and marketing	88,564	65,211	48,220
Research and development	22,033	17,473	12,972
Amortization of intangible assets acquired	2,961	2,114	1,368
General and administrative	30,420	51,309	14,233
Total operating expenses	143,978	136,107	76,793
Income (loss) from operations	21,260	-5,827	12,133
Interest (expense) income, net	-1,446	-23	60
Other (expense) income, net	-1,476	313	532
Income (loss) before (benefit) provision for income taxes	18,338	-5,537	12,725
(Benefit) provision for income taxes	-13,000	-3,890	1,764
Net income (loss)	$31,338	($1,647)	$10,961
Basic net income (loss) per share	$1.44	($0.09)	$0.83
Diluted net income (loss) per share	$1.41	($0.09)	$0.79
Basic weighted average common shares outstanding	21,824	19,325	13,189
Diluted weighted average common shares outstanding	22,195	19,325	13,792

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (Loss) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Statement of Comprehensive Income [Abstract]
Net income (loss)	$31,338	($1,647)	$10,961
Other comprehensive (loss) income components:
Cumulative translation adjustment	-2,318	77	452
Unrealized (loss) gain on marketable securities, net of taxes	-46	23	-10
Total other comprehensive (loss) income	-2,364	100	442
Comprehensive income (loss)	$28,974	($1,547)	$11,403

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Additional Paid-in Capital [Member]	Retained Earnings (Accumulated Deficit) [Member]	Accumulated Other Comprehensive Loss [Member]	Class A and B Common Stock [Member]	Class A and B Common Stock [Member]
In Thousands, except Share data	Total	Additional Paid-in Capital [Member]	Retained Earnings (Accumulated Deficit) [Member]	Accumulated Other Comprehensive Loss [Member]	Class A and B Common Stock [Member]	Treasury Stock [Member]
Beginning Balance at Dec. 31, 2011	$119,627	$124,506	($678)	($2,041)	$13	($2,173)
Beginning Balance, shares at Dec. 31, 2011					12,803,000	-233,000
Stock-based compensation expense	2,913	2,913
Exercise of stock options	7,158	7,157			1
Exercise of stock options, shares					759,000
Tax benefit from stock-based compensation expense in excess of book deductions	1,153	1,153
Public offering of common stock	55,253	55,250			3
Public offering of common stock, shares					2,840,000
Net income (loss)	10,961		10,961
Cumulative translation adjustment	452			452
Unrealized gain (loss) on marketable securities, net of taxes	-10			-10
Ending Balance at Dec. 31, 2012	197,507	190,979	10,283	-1,599	17	-2,173
Ending Balance, shares at Dec. 31, 2012					16,402,000	-233,000
Stock-based compensation expense	3,694	3,694
Exercise of stock options	2,721	2,721
Exercise of stock options, shares					203,000
Tax benefit from stock-based compensation expense in excess of book deductions	563	563
Repurchase of common stock	-15,377					-15,377
Repurchase of common stock, shares						-653,000
Issuance of common stock associated with acquisition of Palomar	141,359	141,353			6
Issuance of common stock associated with acquisition of Palomar, shares					6,028,000
Equity issuance costs associated with acquisition of Palomar	-568	-568
Net income (loss)	-1,647		-1,647
Cumulative translation adjustment	77			77
Unrealized gain (loss) on marketable securities, net of taxes	23			23
Ending Balance at Dec. 31, 2013	328,352	338,742	8,636	-1,499	23	-17,550
Ending Balance, shares at Dec. 31, 2013					22,633,000	-886,000
Stock-based compensation expense	7,114	7,114
Exercise of stock options and vesting of restricted stock units	8,153	8,153
Exercise of stock options, shares	587,359
Exercise of stock options and vesting of restricted stock units, shares					620,000	0
Tax benefit from stock-based compensation expense in excess of book deductions	1,073	1,073
Repurchase of common stock	-15,554					-15,554
Repurchase of common stock, shares						-742,000
Net income (loss)	31,338		31,338
Cumulative translation adjustment	-2,318			-2,318
Unrealized gain (loss) on marketable securities, net of taxes	-46			-46
Ending Balance at Dec. 31, 2014	$358,112	$355,082	$39,974	($3,863)	$23	($33,104)
Ending Balance, shares at Dec. 31, 2014					23,253,000	-1,628,000

Consolidated_Statements_of_Sto1

Consolidated Statements of Stockholders' Equity (Parenthetical) (USD $)	Dec. 31, 2014
Statement of Stockholders' Equity [Abstract]
Class A and B Common Stock	$0.00

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating activities:
Net income (loss)	$31,338	($1,647)	$10,961
Reconciliation of net income (loss) to net cash from operating activities:
Depreciation and amortization	17,546	9,103	6,870
Impairment loss on assets held for sale		607
Stock-based compensation	7,113	3,688	2,910
Loss (gain) on disposal of fixed assets	217	100	-19
Noncash interest expense on capital lease obligations	1,495
Noncash interest expense on license transfer agreement	67
Deferred income taxes	-15,786	-5,284	-352
Net accretion of marketable securities	1,675	1,448	1,480
Changes in operating assets and liabilities, excluding effect of business combinations:
Accounts receivable	-4,864	-9,132	-4,861
Inventories	-8,257	-5,591	-6,183
Net book value of demonstration inventory sold	963	604	884
Prepaid expenses and other current assets	1,183	540	-980
Accounts payable	4,432	-1,724	-151
Due to related party	1,282	-628	347
Tax benefit from stock option exercises	-1,073	-565	-1,178
Accrued expenses	3,331	11,145	4,704
Deferred revenue	1,402	816	-135
Other noncurrent liabilities	42	-102	319
Net cash from operating activities	42,106	3,378	14,616
Investing activities:
Purchases of property and equipment	-15,819	-3,457	-3,116
Proceeds from the sale of property and equipment	41	25,206
Proceeds from the sales and maturities of marketable securities	32,400	84,054	45,400
Purchases of marketable securities	-56,948	-23,088	-69,878
Cash paid for acquisitions, net of cash received	-13,235	-64,978
(Increase) decrease in other assets	-117	-519	110
Net cash (used in) from investing activities	-53,678	17,218	-27,484
Financing activities:
Excess tax benefit on options exercised	1,073	565	1,178
Repurchases of common stock	-15,554	-15,377
Proceeds from public offering of common stock			55,253
Proceeds from stock option exercises	8,153	2,721	7,158
Acquisition-related equity issuance costs		-568
Payments on capital lease obligation	-688	-320	-305
Net cash (used in) from financing activities	-7,016	-12,979	63,284
Effect of exchange rate changes on cash and cash equivalents	64	-19	-53
Net (decrease) increase in cash and cash equivalents	-18,524	7,598	50,363
Cash and cash equivalents, beginning of year	93,655	86,057	35,694
Cash and cash equivalents, end of year	75,131	93,655	86,057
Supplemental cash flow information:
Cash paid for interest	19	25	42
Cash paid for income taxes	2,899	1,030	1,767
Supplemental noncash investing and financing activities:
Transfer of demonstration equipment from inventory to fixed assets	4,135	6,190	2,988
Assets acquired under capital lease	239	14,828	351
Fair value of shares issued in acquisition		$141,359

Nature_of_the_Business

Nature of the Business	12 Months Ended
Nature of the Business	Dec. 31, 2014
Accounting Policies [Abstract]
Nature of the Business	1. Nature of the Business
Nature of the Business	Cynosure, Inc. (“Cynosure” or “the Company”) develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve vaginal health. Cynosure also markets radiofrequency energy sourced medical devices for precision surgical applications such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. Cynosure sells its products through a direct sales force in the United States, Canada, Mexico, France, Morocco, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea and through international distributors in approximately 120 other countries. Cynosure is a Delaware corporation, incorporated on July 10, 1991, located in Westford, Massachusetts.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies
	Significant accounting policies followed in the preparation of these consolidated financial statements are as follows:
	Management Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosures at the date of the financial statements and during the reporting period. Components particularly subject to estimation include the allowance for doubtful accounts, inventory reserves, intangible assets, impairment analysis of goodwill and intangibles, deferred tax assets, liabilities and valuation allowances, fair value of stock options and investments and accrued warranties. On an ongoing basis, management evaluates its estimates. Actual results could differ from these estimates.
	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of Cynosure, Inc. and its wholly owned subsidiaries: Cynosure Securities Corporation, Palomar Medical Products, LLC, Cynosure Mexico, Cynosure Langen GmbH, Cynosure Hamburg GmbH, S.A.R.L. Cynosure France, Cynosure Maroc SARL, Cynosure UK LTD, Cynosure Spain S.L., Cynosure B.V., Cynosure K.K., Suzhou Cynosure Medical Devices Company Ltd., Cynosure Korea Limited, Cynosure Pty Ltd., and Palomar Japan K.K. All intercompany balances and transactions have been eliminated.
	Reclassification
	Certain amounts in prior years’ financial statements have been reclassified to conform to the current year’s presentation within the consolidated statements of operations.
	Cash, Cash Equivalents, Short and Long-Term Marketable Securities
	Cynosure considers all short-term, highly liquid investments with original maturities at the time of purchase of 90 days or less to be cash equivalents. Cynosure accounts for short and long-term marketable securities as available-for-sale in accordance with Accounting Standards Codification (“ASC”) 320, Investments—Debt and Equity Securities Topic. Under ASC 320, securities purchased to be held for indefinite periods of time and not intended at the time of purchase to be held until maturity are classified as available-for-sale securities. ASC 320 requires Cynosure to recognize all marketable securities on the consolidated balance sheets at fair value. Cynosure’s marketable securities are stated at fair value based on quoted market prices. Adjustments to the fair value of marketable securities that are classified as available-for-sale are recorded as increases or decreases, net of income taxes, within accumulated other comprehensive loss in shareholders’ equity. The amortized cost of marketable debt securities is adjusted for amortization of premiums and discounts to maturity computed under the effective interest method. The cost of securities sold is determined by the specific identification method. Cynosure continually evaluates whether any marketable securities have been impaired and, if so, whether such impairment is temporary or other than temporary.
	Fair Value of Financial Instruments
	Cynosure’s financial instruments consist of cash, cash equivalents, short and long-term marketable securities, accounts receivable and capital leases. Cynosure’s estimate of fair value for financial instruments, other than marketable securities, which are carried at fair value, approximates their carrying value at December 31, 2014 and 2013.
	ASC 820, Fair Value Measurement Topic, applies to all financial assets and financial liabilities that are being measured and reported on a fair value basis, establishes a framework for measuring fair value of assets and liabilities and expands disclosures about fair value measurements.
	Concentration of Credit Risk
	Financial instruments that subject Cynosure to credit risk consist primarily of cash and cash equivalents, short and long-term marketable securities and accounts receivable. Cynosure places cash and cash equivalents and short and long-term marketable securities in established financial institutions. Cynosure has no significant off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements. Cynosure’s accounts receivable balance, net of allowance for doubtful accounts, was $42.5 million as of December 31, 2014, compared with $36.6 million as of December 31, 2013. The allowance for doubtful accounts as of December 31, 2014 and 2013 was $2.9 million and $1.8 million, respectively. Cynosure maintains an allowance for doubtful accounts based upon the aging of its receivable balances, known collectibility issues and Cynosure’s historical experience with losses. Cynosure works to mitigate bad debt exposure through its credit evaluation policies, reasonably short payment terms and geographical dispersion of sales. Losses from bad debt have historically been within management’s estimates. Cynosure’s revenue includes export sales to foreign companies located principally in Europe, the Asia/Pacific region and the Middle East. Cynosure obtains letters of credit for foreign sales that the Company considers to be at risk.
	No customer accounted for 10% or greater of revenue during 2014, 2013 or 2012. No customer accounted for 10% or greater of accounts receivable as of December 31, 2014 or 2013. Accounts receivable allowance activity consisted of the following for the years ended December 31:


			2014				2013				2012
			(In thousands)
	Balance at beginning of year		$	1,803			$	2,043			$	1,872
	Additions			2,373				1,058				591
	Deductions			(1,227	)			(1,298	)			(420	)

	Balance at end of year		$	2,949			$	1,803			$	2,043


	Inventory
	Cynosure states all inventories at the lower of cost or market, determined on a first-in, first-out method. Inventory includes material, labor and overhead and consists of the following:


			December 31,
			2014				2013 (recast)
			(In thousands)
	Raw materials		$	16,875			$	16,900
	Work in process			3,526				2,316
	Finished goods			38,917				31,035

			$	59,318			$	50,251

	Included in finished goods are lasers used for demonstration purposes. Cynosure’s policy is to include demonstration lasers as inventory for a period of up to one year after being used by the sales force at which time the demonstration lasers are either sold or transferred to fixed assets at the lower of cost or market and depreciated over their estimated useful life of three years. Similar to any other finished goods in inventory, Cynosure accounts for such demonstration inventory in accordance with the policy for excess and obsolescence review of Cynosure’s entire inventory.
	Cynosure’s excess and obsolescence reserve policy is to establish inventory reserves when conditions exist that suggest that inventory may be in excess of anticipated demand or is obsolete based upon assumptions about future demand for products and market conditions. Cynosure regularly evaluates the ability to realize the value of inventory based on a combination of factors including the following: historical usage rates, forecasted sales or usage, product end of life dates, estimated current and future market values and new product introductions.
	Cynosure purchases raw material components as well as certain finished goods from sole source suppliers. A delay in the production capabilities of these vendors could cause a delay in Cynosure’s manufacturing, and a possible loss of revenues, which would adversely affect operating results.
	Property and Equipment
	Property and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Assets under capital leases and leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the respective lease term. Included in property and equipment are certain lasers that are used for demonstration purposes. Maintenance and repairs are charged to expense as incurred. Cynosure continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. Cynosure evaluates the realizability of its long-lived assets based on profitability and cash flow expectations for the related asset. Any write-downs are treated as permanent reductions in the carrying amount of the assets. Based on this evaluation, Cynosure believes that, as of each of the balance sheet dates presented, none of Cynosure’s long-lived assets were impaired.
	Intangible Assets
	Cynosure capitalizes and includes in intangible assets the costs of developed technology and patents, customer relationships, trade names and business licenses. Intangible assets are recorded at fair value and stated net of accumulated amortization and impairments. Cynosure amortizes its intangible assets that have finite lives using either the straight-line or accelerated method, based on the useful life of the asset over which it is expected to be consumed utilizing expected undiscounted future cash flows. Amortization is recorded over the estimated useful lives ranging from five to 23 years. Cynosure evaluates the realizability of its definite lived intangible assets whenever events or changes in circumstances or business conditions indicate that the carrying value of these assets may not be recoverable based on expectations of future undiscounted cash flows for each asset group. If the carrying value of an asset or asset group exceeds its undiscounted cash flows, Cynosure estimates the fair value of the assets, generally utilizing a discounted cash flow analysis based on the present value of estimated future cash flows to be generated by the assets using a risk-adjusted discount rate. To estimate the fair value of the assets, Cynosure uses market participant assumptions pursuant to ASC 820, Fair Value Measurements. If the estimate of an intangible asset’s remaining useful life is changed, Cynosure will amortize the remaining carrying value of the intangible asset prospectively over the revised useful life.
	Goodwill
	Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination. Cynosure does not amortize its goodwill, but instead tests for impairment at least annually and more frequently whenever events or changes in circumstances indicate that the fair value of the asset may be less than its carrying value of the asset. Cynosure’s annual test for impairment occurs on the first day of its fourth quarter.
	Cynosure has adopted Accounting Standards Update (“ASU”) 2011-08 Intangibles—Goodwill and Other, an amendment to ASC 350, which updates how an entity will evaluate its goodwill for impairment. The guidance provides entities an option to perform a “qualitative” assessment to determine whether further impairment testing is necessary. If further testing is required, the test for impairment continues with the two step process. The first step compares the carrying amount of the reporting unit to its estimated fair value (Step 1). To the extent that the carrying value of the reporting unit exceeds its estimated fair value, a second step is performed, wherein the reporting unit’s carrying value is compared to the implied fair value (Step 2). To the extent that the carrying value exceeds the implied fair value, impairment exists and must be recognized.
	Cynosure has one reporting unit for goodwill impairment testing and has performed a qualitative assessment on that reporting unit. As a result of this assessment, the Company determined that goodwill is not impaired as of December 31, 2014 and 2013.
	Revenue Recognition and Deferred Revenue
	Cynosure generates revenue from the sale of non-invasive and minimally invasive light-based aesthetic treatment applications, as well as radiofrequency energy based surgical and aesthetic applications. Cynosure offers service and warranty contracts in connection with these sales.
	Cynosure recognizes revenue from sales of aesthetic treatment systems and parts and accessories in accordance with the Revenue Recognition Topic ASC 605-10-S99. Cynosure recognizes revenue from sales of its treatment systems and parts and accessories upon delivery, provided there are no uncertainties regarding customer acceptance, there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collectibility of the related receivable is reasonably assured. Revenues from the sales of service and warranty contracts are deferred and recognized on a straight-line basis over the contract period as services are provided. Payments received by Cynosure in advance of product delivery or performance of services are deferred until earned.
	Cynosure recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured. As such, Cynosure recognizes royalty revenues in the quarter reported to the Company by its licensees, or one quarter following the quarter in which sales by Cynosure’s licensees occurred. Royalty revenues also include amounts due from settlements with licensees for back-owed royalties from prior periods. These settlement amounts are considered revenue, when collectability is reasonably assured, because they constitute Cynosure’s ongoing major or central operations.

	In December 2013, Cynosure completed a comprehensive settlement agreement with Tria Beauty, Inc. (“Tria”) which ended the patent infringement litigation between Tria and Palomar Medical Technologies, Inc. (“Palomar”). Under the agreement, Cynosure is entitled to receive $10.0 million plus future royalty payments. Cynosure will pay approximately $2.0 million of this revenue to Massachusetts General Hospital (“MGH”) under an exclusive license agreement between Palomar and MGH, which will be recorded as cost of revenues within Cynosure’s consolidated statement of operations. Cynosure recognized $3.0 million and $4.0 million of this revenue in the years ended December 31, 2014 and 2013, respectively which is recorded as royalty revenues within Cynosure’s consolidated statement of operations. Cynosure recognized $0.8 million and $1.0 million in cost of revenues in the years ended December 31, 2014 and 2013, respectively, related to this revenue.
	Multiple-element arrangements are evaluated in accordance with the principles of ASU 2009-13, Revenue Recognition Topic—Multiple Element Arrangements and Cynosure allocates revenue among the elements based upon each element’s relative fair value.
	In accordance with the provisions of ASC 605-45, Revenue Recognitions Topic—Principal Agent Considerations, Cynosure records shipping and handling costs billed to its customers as a component of revenue, and the underlying expense as a component of cost of revenue. Shipping and handling costs included as a component of revenue totaled approximately $1.0 million, $0.6 million, and $0.4 million for the years ended December 31, 2014, 2013 and 2012, respectively. Shipping and handling costs included as a component of cost of revenue totaled $1.1 million, $0.6 million and $0.5 million for the years ended December 31, 2014, 2013 and 2012, respectively.
	Cynosure collects sales tax from its customers on product sales for which the customer is not tax exempt and remits such taxes to the appropriate governmental authorities. Cynosure presents its sales taxes on a net basis; therefore, these taxes are excluded from revenues. Cynosure records medical device costs billed to its customers as a component of revenue and the underlying expense as a component of cost of revenue.
	Cost of Revenues
	Cynosure’s cost of revenues consist primarily of material, labor and manufacturing overhead expenses and includes the cost of components and subassemblies supplied by third party suppliers. Cost of revenues also includes royalties incurred on certain products sold by Cynosure and its licensees, costs incurred in connection with Cynosure’s efforts to litigate or settle additional third-party license agreements, amortization expense related to developed technology and patents intangible assets, service and warranty expenses, as well as salaries and personnel-related expenses, including stock-based compensation, for Cynosure’s operations management team, purchasing and quality control.
	Product Warranty Costs
	Cynosure typically provides a one-year parts and labor warranty on end-user sales of lasers. Distributor sales generally include a one-year warranty on parts only. Estimated future costs for initial product warranties are provided for at the time of revenue recognition. The following table sets forth activity in the accrued warranty account, which is a component of accrued expenses in the consolidated balance sheets:


		Years Ended December 31,
		2014				2013				2012
		(In thousands)
Balance at beginning of year		$	6,651			$	3,415			$	3,171
Warranty provision related to new sales			15,104				9,114				4,641
Warranty provision assumed from acquisitions			—				1,422				—
Costs incurred			(13,637	)			(7,300	)			(4,397	)

Balance at end of year		$	8,118			$	6,651			$	3,415


Research and Development
Research and development costs consist of salaries and other personnel-related expenses, including stock-based compensation, of employees primarily engaged in research, development and engineering activities and materials used and other overhead expenses incurred in connection with the design and development of Cynosure’s products and from time to time expenses associated with collaborative research agreements that the Company may enter into. These costs are expensed as incurred.
Advertising Costs
Cynosure expenses advertising costs as incurred. Advertising costs totaled $1.2 million, $1.1 million and $0.6 million for the years ended December 31, 2014, 2013 and 2012, respectively.
Foreign Currency Translation
The financial statements of Cynosure’s foreign subsidiaries are translated from local currency into U.S. dollars using the current exchange rate at the balance sheet date for assets and liabilities, and the average exchange rate prevailing during the period for revenue and expenses. The functional currency for Cynosure’s foreign subsidiaries is considered to be the local currency for each entity and, accordingly, translation adjustments for these subsidiaries are included in accumulated other comprehensive loss within stockholders’ equity. Certain intercompany and third party foreign currency-denominated transactions generated foreign currency remeasurement (losses) gains of approximately $(1.6 million), $0.3 million and $0.4 million during 2014, 2013 and 2012, respectively, which are included in other (expense) income, net, in the consolidated statements of operations.
Accumulated Other Comprehensive Loss
Changes to accumulated other comprehensive loss during the year ended December 31, 2014 were as follows (in thousands):


		Unrealized				Translation				Accumulated
		Loss on				Adjustment				Other
		Marketable								Comprehensive
		Securities, net								Loss
		of taxes
Balance—December 31, 2013		$	36			$	(1,535	)		$	(1,499	)
Current period other comprehensive loss			(46	)			(2,318	)			(2,364	)

Balance—December 31, 2014		$	(10	)		$	(3,853	)		$	(3,863	)
Stock-Based Compensation
Cynosure follows the fair value recognition provisions of ASC 718, Stock Compensation Topic. This guidance requires share-based payments to employees, including grants of employee stock options and restricted stock units (“RSUs”), to be recognized in the statement of operations based on their fair values at the date of grant. Cynosure expenses the fair value of share-based payments over the service period. ASC 718 requires companies to utilize an estimated forfeiture rate when calculating the expense for the period. Accordingly, Cynosure reviews its actual forfeiture rates and periodically aligns its stock compensation expense with the share-based payments that are vesting. Cynosure recorded stock-based compensation expense of $7.1 million, $3.7 million and $2.9 million for the years ended December 31, 2014, 2013 and 2012, respectively. As of both December 31, 2014 and 2013, Cynosure had $23,000 of stock-based compensation expense capitalized as a part of inventory.

Total stock-based compensation expense was recorded to cost of revenues and operating expenses based upon the functional responsibilities of the individual holding the respective share-based payments, as follows:


		Years Ended December 31,
		2014				2013				2012
		(In thousands)
Cost of revenues		$	292			$	174			$	127
Sales and marketing			1,934				1,090				857
Research and development			1,007				594				495
General and administrative			3,880				1,830				1,431

Total stock-based compensation expense		$	7,113			$	3,688			$	2,910

As of December 31, 2014, there was $10.1 million of unrecognized compensation expense related to non-vested share awards that is expected to be recognized on a straight-line basis over a weighted average period of 1.6 years. Cash received from option exercises was $8.2 million, $2.7 million and $7.2 million during the years ended December 31, 2014, 2013 and 2012, respectively.
Cynosure granted 854,180, 617,510 and 405,790 stock options during the years ended December 31, 2014, 2013 and 2012, respectively. Cynosure uses the Black-Scholes option pricing model to determine the weighted average fair value of options. The weighted average fair value of the options granted during the years ended December 31, 2014, 2013 and 2012 was $10.50, $10.25 and $9.23, respectively, using the following assumptions:


		Years Ended December 31,
		2014		2013		2012
Risk-free interest rate		1.41% - 1.80%		0.33% - 1.49%		0.61% - 0.86%
Expected dividend yield		—		—		—
Expected term		4.6 years		2 years - 4.8 years		5.8 years
Expected volatility		43% - 44%		44% - 56%		56% - 57%
Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. Cynosure’s estimated expected stock price volatility is based on its own historical volatility for the 2014, 2013 and 2012 periods. Cynosure’s expected term of options granted during the years ended December 31, 2014 and 2013 represents the weighted average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and Cynosure’s historical exercise patterns. Cynosure’s expected term of options granted during the year ended December 31, 2012 was derived from the simplified method described in ASC 718-10-S99. The risk-free rate for the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield of zero is based on the fact that Cynosure has never paid cash dividends and has no present intention to pay cash dividends.
Cynosure granted 44,840 RSUs during the year ended December 31, 2014 to employees at a fair market value of its common stock on the date of grant and which vest annually over a three-year period. Cynosure is recognizing related compensation expense on a straight-line basis over the three-year period.
Cynosure granted 43,500 RSUs during the year ended December 31, 2014 to non-employee directors at a fair market value of its common stock on the date of grant and which vest quarterly over a one-year period. Cynosure is recognizing related compensation expense on a straight-line basis over the one-year period.
Interest (Expense) Income, net
Interest (expense) income consists primarily of interest charges on capital lease obligations, and interest earned on Cynosure’s short and long-term marketable securities consisting of state and municipal bonds, U.S. government agencies and treasuries, corporate obligations and commercial paper. Cynosure expects interest expense to remain consistent in 2015 as compared to 2014.

Income Taxes
Cynosure provides for income taxes in accordance with ASC 740, Accounting for Income Taxes. ASC 740 recognizes tax assets and liabilities for the cumulative effect of all temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities, and are measured using the enacted tax rates that will be in effect when these differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Cynosure considers several sources of taxable income in making its valuation allowance assessments including taxable income in carryback years, future reversals of existing taxable temporary differences, tax planning strategies and forecasted future income.
Cynosure accounts for uncertain tax positions following the provisions of ASC 740. ASC 740 clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. ASC 740 also provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition.
Net Income (Loss) per Share
Basic net income (loss) per share is determined by dividing net income (loss) by the weighted average common shares outstanding during the period. Diluted net income (loss) per share is determined by dividing net income (loss) by the diluted weighted average shares outstanding during the period. Diluted weighted average shares reflect the dilutive effect, if any, of common stock options and RSUs based on the treasury stock method. For the years ended December 31, 2014, 2013 and 2012, there were no outstanding Class B shares, and Cynosure may not issue Class B shares in the future.
The reconciliation of basic and diluted weighted average shares outstanding for the years ended December 31, 2014, 2013 and 2012 is as follows (in thousands, except per share data):


		Years Ended December 31,
		2014				2013				2012
Net income (loss)		$	31,338			$	(1,647	)		$	10,961

Basic weighted average common shares outstanding			21,824				19,325				13,189
Weighted average common stock equivalents			371				—				603

Diluted weighted average common shares outstanding			22,195				19,325				13,792

Basic net income (loss) per share		$	1.44			$	(0.09	)		$	0.83

Diluted net income (loss) per share		$	1.41			$	(0.09	)		$	0.79

For the year ended December 31, 2014, approximately 0.5 million shares of Cynosure’s Class A common stock issuable pursuant to options and RSUs were excluded from the calculation of diluted weighted average common shares outstanding as their effect was antidilutive.
For the year ended December 31, 2013, the number of basic and diluted weighted average shares outstanding was the same because any increase in the number of shares of common stock equivalents for that period would be antidilutive based on the net loss for the period. During the year ended December 31, 2013, outstanding options to purchase 1.3 million shares were excluded from the computation of diluted earnings per share because their inclusion would have been antidilutive.
For the year ended December 31, 2012, options to purchase approximately 0.7 million shares of Cynosure’s Class A common stock were excluded from the calculation of diluted weighted average common shares outstanding as their effect was antidilutive.

Recent Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board issued guidance codified in ASC 606, Revenue Recognition—Revenue from Contracts with Customers, which amends the guidance in ASC 605, Revenue Recognition. This new revenue standard creates a single source of revenue guidance for all companies in all industries and is more principles-based than the current revenue guidance. The new guidance must be adopted using either a full retrospective approach for all periods presented in the period of adoption or a modified retrospective approach. ASC 606 is effective for interim and annual periods beginning after December 15, 2016. Cynosure is currently evaluating the impact of the provisions of ASC 606.

Fair_Value

Fair Value	12 Months Ended
Fair Value	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value	3. Fair Value
	U.S. GAAP establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:

		•		Level 1—Quoted prices in active markets for identical assets or liabilities.

		•		Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable markets data for substantially the full term of the assets or liabilities.

		•		Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The following table represents Cynosure’s fair value hierarchy for its financial assets (cash equivalents and marketable securities) measured at fair value as of December 31, 2014 (in thousands):


			Level 1		Level 2		Level 3		Total
	Money market funds(1)		$	1,753	$	—	$	—	$	1,753
	State and municipal bonds			—		47,744		—		47,744
	Treasuries and government agencies			—		8,486		—		8,486
	Corporate obligations and commercial paper			—		2,001		—		2,001
	Equity securities			13		—		—		13

	Total		$	1,766	$	58,231	$	—	$	59,997


	-1	Included in cash and cash equivalents at December 31, 2014.
	The following table represents Cynosure’s fair value hierarchy for its financial assets (cash equivalents and marketable securities) measured at fair value as of December 31, 2013 (in thousands):


			Level 1		Level 2		Level 3		Total
	Money market funds(1)		$	5,185	$	—	$	—	$	5,185
	State and municipal bonds(2)			—		18,133		—		18,133
	Treasuries and government agencies			—		15,028		—		15,028
	Corporate obligations and commercial paper			—		3,020		—		3,020
	Equity securities			49		—		—		49

	Total		$	5,234	$	36,181	$	—	$	41,415


	-1	Included in cash and cash equivalents at December 31, 2013.
	-2	$0.8 million included in cash and cash equivalents at December 31, 2013.

Short_and_LongTerm_Marketable_

Short and Long-Term Marketable Securities	12 Months Ended
Short and Long-Term Marketable Securities	Dec. 31, 2014
Investments, Debt and Equity Securities [Abstract]
Short and Long-Term Marketable Securities	4. Short and Long-Term Marketable Securities
	Cynosure’s available-for-sale securities at December 31, 2014 consist of approximately $58.2 million in investments in debt securities consisting of state and municipal bonds, treasuries and government agencies, corporate obligations and commercial paper and approximately $13,000 in equity securities. All investments in available-for-sale securities are recorded at fair market value, with any unrealized gains and losses reported as a separate component of accumulated other comprehensive loss. As of December 31, 2014, Cynosure’s marketable securities consist of the following (in thousands):


			Market			Amortized			Unrealized			Unrealized
			Value			Cost			Gains			Losses
	Available-for-Sale Securities:
	Short-term marketable securities:
	State and municipal bonds		$	26,041		$	26,033		$	8		$	—
	Treasuries and government agencies			4,000			4,000			—			—
	Corporate obligations and commercial paper			2,001			2,001			—			—
	Equity securities			13			18			—			(5	)

	Total short-term marketable securities		$	32,055		$	32,052		$	8		$	(5	)

	Long-term marketable securities:
	State and municipal bonds		$	21,703		$	21,721		$	2		$	(20	)
	Treasuries and government agencies			4,486			4,500			—			(14	)

	Total long-term marketable securities		$	26,189		$	26,221		$	2		$	(34	)

	Total available-for-sale securities		$	58,244		$	58,273		$	10		$	(39	)

	Total marketable securities		$	58,244

	As of December 31, 2013, Cynosure’s marketable securities consist of the following (in thousands):


			Market			Amortized			Unrealized			Unrealized
			Value			Cost			Gains			Losses
	Available-for-Sale Securities:
	Cash equivalents:
	State and municipal bonds		$	793		$	793		$	—		$	—

	Total cash equivalents		$	793		$	793		$	—		$	—

	Short-term marketable securities:
	State and municipal bonds		$	10,552		$	10,551		$	1		$	—
	Treasuries and government agencies			15,028			15,018			10			—
	Corporate obligations and commercial paper			1,004			1,004			—			—
	Equity securities			49			8			41			—

	Total short-term marketable securities		$	26,633		$	26,581		$	52		$	—

	Long-term marketable securities:
	State and municipal bonds		$	6,788		$	6,787		$	1		$	—
	Corporate obligations and commercial paper			2,016			2,015			1			—

	Total long-term marketable securities		$	8,804		$	8,802		$	2		$	—

	Total available-for-sale securities		$	36,230		$	36,176		$	54		$	—

	Total marketable securities		$	35,437


	As of December 31, 2014, Cynosure’s available-for-sale debt securities mature as follows (in thousands):


						Maturities
			Total			Less Than One Year			One to Five Years			More than five years
	State and municipal bonds		$	47,744		$	26,041		$	21,703		$	—
	Treasuries and government agencies			8,486			4,000			4,486			—
	Corporate obligations and commercial paper			2,001			2,001			—			—

Total available-for-sale debt securities		$	58,231		$	32,042		$	26,189		$	—

Acquisition

Acquisition	12 Months Ended
Acquisition	Dec. 31, 2014
Business Combinations [Abstract]
Acquisition	5. Acquisition
	Ellman International, Inc.
	On September 5, 2014, Cynosure acquired substantially all of the assets of Ellman International, Inc. (“Ellman”) for $13.2 million in cash. In addition, Cynosure assumed current liabilities associated with normal working capital and certain contractual liabilities. The purchase price was based primarily on the net working capital on the date of purchase plus an amount to retire all of Ellman’s long term debt on the date of sale. Cynosure also assumed a license transfer agreement as part of the purchase valued at $4.2 million, which is classified as a liability. The acquisition complements Cynosure’s aesthetic treatment platform with radiofrequency energy sources and accessory products. The acquisition of Ellman was considered a business acquisition for accounting purposes.
	Cynosure retained an independent valuation firm to assess the fair value of the assets acquired and liabilities assumed. Pro forma financial information was filed with the SEC within the applicable time period. Cynosure has allocated the purchase price to the net tangible and intangible assets based on their estimated fair values as of September 5, 2014. During the fourth quarter of 2014, Cynosure completed its fair value procedures on the intangible assets, fixed assets and the license transfer agreement acquired in the acquisition of Ellman. As such, the fair value of the accounts receivable, inventory, prepaid and other assets acquired, along with the accounts payable, accrued expenses and deferred revenue assumed presented in the table below are provisional and will be finalized in a later period once the fair value procedures are completed. Goodwill represents the excess of purchase price over the fair value of the net assets acquired. During the fourth quarter of 2014, Cynosure revised its estimates of the assets acquired and liabilities assumed in regards to the acquisition of Ellman, and as a result, increased goodwill from $5.9 million at September 30, 2014 to $6.6 million at December 31, 2014. Inventory decreased by $0.7 million, due primarily to adjustments to the inventory reserve and the reclassification of demonstration equipment to fixed assets, per Cynosure policy.
	The following table summarizes the estimated fair value as of September 5, 2014 of the net assets acquired (in thousands):


	Purchase price:
	Cash paid	$	13,235

	Total	$	13,235

	Assets (liabilities) acquired:
	Accounts receivable		2,147
	Inventory		3,682
	Prepaid and other assets		488
	Fixed assets		612
	Intangible assets		6,800
	Goodwill		6,598
	Accounts payable		(9	)
	Accrued expenses		(2,469	)
	Deferred revenue		(454	)
	License transfer agreement		(4,160	)

	Total	$	13,235


	Revenue related to Ellman’s operations was $11.5 million for the period following the September 5, 2014 acquisition date, and is included in Cynosure’s consolidated statements of operations for the year ended December 31, 2014. As a result of the integration of the operations of Ellman into Cynosure’s operations, disclosures of earnings included in the accompanying consolidated statement of operations since the acquisition date is not practicable.
	The following unaudited pro forma condensed consolidated operating results for the years ended December 31, 2014 and 2013 summarize the combined results of operations for Cynosure and Ellman. The unaudited pro forma condensed consolidated operating results includes the business combination accounting effects as if the acquisition had been completed as of January 1, 2013 (for both the 2014 and 2013 period results) after giving effect to certain adjustments. These pro forma financial statements are for informational purposes only and are not necessarily indicative of the operating results that would have occurred if the transaction had occurred on such date. No effect has been given for synergies, if any, that may be realized through the acquisition.


		Year Ended
		December 31,
		2014			2013
	Revenue (unaudited, in thousands)	$	308,980		$	255,077
	Pre-tax income (loss) (unaudited, in thousands)	$	17,978		$	(12,261	)
	The unaudited consolidated pro forma financial information above includes significant, non-recurring adjustments made to account for certain costs which would have been incurred if the acquisition had been completed on January 1, 2013, including $0.3 million associated with the step up in fair value of finished goods inventory acquired through the acquisition.
	During the year ended December 31, 2014, Cynosure incurred $0.7 million in general and administrative costs associated with the acquisition of Ellman.
	Palomar Medical Technologies, Inc.
	On June 24, 2013, Cynosure acquired Palomar. Certain adjustments related to Palomar’s opening balance sheet were finalized during the first half of 2014, after the December 31, 2013 financial statements were issued. The adjustments were based on facts that existed at the acquisition date and were finalized using information that came available during the first half of 2014. Under ASC 805, Business Combinations, an acquirer is required to recognize adjustments to provisional amounts during the measurement period as they are identified, and to recognize such adjustments retrospectively—as if the accounting from the business combination had been completed at the acquisition date. As a result, the carrying amount of inventory acquired in the acquisition of Palomar was retrospectively decreased by $3.8 million on June 24, 2013, and the carrying amounts of the deferred tax liability and accounts payable acquired in the acquisition of Palomar were retrospectively increased by $0.2 million and $0.1 million, respectively, on June 24, 2013, with corresponding increases to goodwill. The carrying amount of accrued expenses acquired in the acquisition of Palomar was retrospectively decreased by $23,000 on June 24, 2013, with a corresponding decrease to goodwill. The December 31, 2013 consolidated balance sheet within this Annual Report has been updated to disclose these recast values.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	12 Months Ended
Goodwill and Other Intangible Assets	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	6. Goodwill and Other Intangible Assets
	Changes to goodwill during the year ended December 31, 2014 were as follows (in thousands):


	Balance—December 31, 2013 (recast)	$	99,237
	Ellman acquisition		6,598
	Translation adjustment		(71	)

	Balance—December 31, 2014	$	105,764


	Other intangible assets consist of the following at December 31, 2014 and December 31, 2013 (in thousands):


		Developed			Business			Customer			Trade			Other			Total
		Technology			Licenses			Relationships			Names
		& Patents
	December 31, 2014
	Cost	$	29,240		$	384		$	19,718		$	18,390		$	1,338		$	69,070
	Translation adjustment		—			34			2			—			2			38
	Accumulated amortization		(7,840	)		(252	)		(5,818	)		(1,607	)		(8	)		(15,525	)

	Balance, December 31, 2014	$	21,400		$	166		$	13,902		$	16,783		$	1,332		$	53,583

	December 31, 2013
	Cost	$	27,510		$	384		$	15,833		$	16,930		$	1,338		$	61,995
	Translation adjustment		—			40			26			—			4			70
	Accumulated amortization		(2,216	)		(239	)		(3,662	)		(761	)		(8	)		(6,886	)

	Balance, December 31, 2013	$	25,294		$	185		$	12,197		$	16,169		$	1,334		$	55,179

	Cynosure acquired $6.8 million of identifiable intangible assets in the Ellman acquisition, of which $1.7 million was assigned to technology patents, $3.6 million was assigned to customer relationships and $1.5 million was assigned to trademarks. The technology patents are being amortized on an economic patterned basis over a 7.0 year weighted-average amortization period and the customer relationships and trademarks are being amortized on a straight-line basis over a 15.0 year weighted-average amortization period. In total, the weighted-average amortization period for these intangible assets is 13.0 years.
	Amortization expense related to developed technology and patents is classified as a component of cost of revenues. Amortization expense related to customer relationships and trade names is classified as a component of amortization of intangible assets acquired. Amortization expense related to business licenses and other is classified as a component of general and administrative expenses. For the year ended December 31, 2014, Cynosure recognized $0.1 million in amortization expense, classified as a component of amortization of intangible assets acquired, and $0.1 million in amortization expense, classified as a component of cost of revenues, related to the identifiable intangible assets from the Ellman acquisition.
	Amortization expense for the years ended December 31, 2014, 2013 and 2012 was $8.6 million, $3.1 million and $1.9 million, respectively. Cynosure has approximately $1.3 million of indefinite-life intangible assets that are included in other intangible assets in the table above. As of December 31, 2014, amortization expense on existing definite-lived intangible assets for the next five years and beyond is as follows (table in thousands):


	2015	$	9,223
	2016		8,434
	2017		6,444
	2018		4,928
	2019		3,189
	2020 and Thereafter		20,405

	Total	$	52,623

Segment_and_Geographic_Informa

Segment and Geographic Information	12 Months Ended
Segment and Geographic Information	Dec. 31, 2014
Segment Reporting [Abstract]
Segment and Geographic Information	7. Segment and Geographic Information
	In accordance with ASC 280, Segment Reporting Topic, operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. Cynosure’s chief decision-maker, as defined under ASC 280, is a combination of the Chief Executive Officer and the Chief Financial Officer. Cynosure views its operations and manages its business as one segment, aesthetic treatment products and services.
	The following table represents total revenue by geographic destination:


		Year Ended December 31,
		2014			2013			2012
		(In thousands)
	United States	$	148,803		$	111,179		$	72,704
	Europe		50,513			39,529			28,808
	Asia/Pacific		64,651			52,574			39,991
	Other		28,402			22,728			11,990

		$	292,369		$	226,010		$	153,493

	Total assets by geographic area are as follows:


		December 31,
		2014			2013
		(In thousands)
	United States	$	420,513		$	380,383
	Europe		23,235			21,741
	Asia/Pacific		19,182			16,437
	Eliminations		(5,206	)		(3,860	)

		$	457,724		$	414,701

	Long-lived assets (property and equipment only) by geographic area are as follows:


		December 31,
		2014			2013
		(In thousands)
	United States	$	30,912		$	24,004
	Europe		1,656			1,326
	Asia/Pacific		1,688			1,115

		$	34,256		$	26,445

	No individual country within Europe or Asia/Pacific represented greater than 10% of total revenue, total assets or total long-lived assets for any period presented.

Balance_Sheet_Accounts

Balance Sheet Accounts	12 Months Ended
Balance Sheet Accounts	Dec. 31, 2014
Text Block [Abstract]
Balance Sheet Accounts	8. Balance Sheet Accounts
	Property and Equipment
	Property and equipment consists of the following at December 31:


			Estimated		2014			2013
			Useful		Cost			Cost
			Life
			(Years)
			(In thousands)
	Equipment			5-Mar	$	9,834		$	7,835
	Furniture and fixtures			5-Mar		3,008			2,698
	Computer equipment and software			3		5,095			5,047
	Leased equipment			4-Mar		1,625			1,660
	Leased buildings			14		13,327			13,327
	Leasehold improvements			5		12,611			2,898
	Demonstration equipment			3		20,246			24,094
	Construction in-progress					42			495

						65,788			58,054
	Less: Accumulated depreciation and amortization					(31,532	)		(31,609	)

					$	34,256		$	26,445

	Depreciation expense relating to property and equipment was $8.9 million, $6.0 million and $5.0 million for the years ended December 31, 2014, 2013 and 2012, respectively. As of December 31, 2014 and 2013, the cost of assets recorded under capitalized leases was approximately $15.0 million and $15.0 million, respectively, and the related accumulated amortization was approximately $2.4 million and $1.2 million, respectively. Amortization expense of assets recorded under capitalized leases is included as a component of depreciation expense.
	Accrued Expenses
	Accrued expenses consist of the following at December 31:


			2014		2013
			(In thousands)
	Accrued payroll and payroll taxes		$	7,390	$	9,547
	Accrued employee benefits			1,688		2,093
	Accrued warranty costs			8,118		6,651
	Accrued commissions			6,457		5,243
	Accrued income, value-added and sales taxes			5,730		3,319
	Accrued royalties			3,937		2,459
	Accrued other			9,106		7,642

			$	42,426	$	36,954

	Other Noncurrent Liabilities
	Other noncurrent liabilities consist of the following at December 31:


			2014		2013
			(In thousands)
	Noncurrent deferred rent		$	181	$	2
	Noncurrent deferred tax liability			1,347		8,673
	Noncurrent income tax reserve			—		51
	Noncurrent tenant improvement allowances			2,743		—
	License transfer agreement(1)			4,054		—

			$	8,325	$	8,726


	-1	On July 31, 2014, prior to Cynosure’s acquisition of Ellman, Ellman agreed to a binding license settlement with its previous owners. Ellman agreed to pay a future fixed payment commitment of $0.3 million in January 2015 and 2016 and $0.4 million each year from December 31, 2016 to December 31, 2028. Cynosure assumed this commitment, which is referred to as a license transfer agreement, as part of its purchase of substantially all of the assets of Ellman. The license transfer agreement was valued at $4.2 million as of the September 5, 2014 acquisition date using an interest rate of 4.75%. The current portion of $0.1 million is included within accrued expenses and the remainder of $4.1 million is classified as a component of other noncurrent liabilities within Cynosure’s December 31, 2014 consolidated balance sheet.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2014
Equity [Abstract]
Stockholders' Equity	9. Stockholders’ Equity
	Common Stock Authorized
	Cynosure has a dual-class capital structure consisting of $0.001 par value Class A common stock and Class B common stock. Cynosure has authorized 61,500,000 shares of $0.001 par value Class A common stock and 8,500,000 shares of $0.001 par value Class B common stock.
	As of December 31, 2014, there were 23,253,065 shares of Class A common stock and no shares of Class B common stock issued.
	The rights, preferences and privileges of Class A common stock are as follows:
	Voting Rights
	The holders of Class A common stock will be entitled to one vote per share with respect to each matter presented to Cynosure stockholders on which the holders of common stock are entitled to vote.
	Conversion
	Cynosure’s Class A common stock is not convertible into any other shares of Cynosure’s capital stock.
	Dividends
	Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of Class A common stock shall be entitled to share equally, on a per share basis, in any dividends that Cynosure’s board of directors may determine to issue from time to time.
	Liquidation Rights
	In the event of Cynosure’s liquidation or dissolution, the holders of Class A common stock shall be entitled to share equally, on a per share basis, in all assets remaining after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock.
	Preferred Stock
	Cynosure has authorized 5,000,000 shares of $0.001 par value preferred stock. The Board of Directors has full authority to issue this stock and to fix the voting powers, preference rights, qualifications, limitations, or restrictions thereof, including dividend rights, conversion rights, redemption privileges and liquidation preferences and the number of shares constituting any series or designation of such series.

	Treasury Stock
	On October 29, 2013, Cynosure announced that its board of directors authorized the repurchase of up to $25 million of its Class A common stock, from time to time, on the open market or in privately negotiated transactions under a stock repurchase program. On April 30, 2014, Cynosure’s board of directors approved an increase of $10 million to the stock repurchase program. The program will terminate upon the purchase of $35 million in common stock or expiration of the program on November 1, 2015. During the year ended December 31, 2014, Cynosure repurchased 742,179 shares of its common stock at an aggregate cost of $15.6 million and at a weighted average price of $20.96 per share under this program. As of December 31, 2014, approximately $4.1 million remains available to repurchase shares under the program. As of December 31, 2014, Cynosure has repurchased an aggregate of 1,395,480 shares under this program at an aggregate cost of $30.9 million.

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
Stock-Based Compensation	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	10. Stock-Based Compensation
	2004 Stock Option Plan
	In October 2004, the Board of Directors adopted and the stockholders approved the 2004 Stock Option Plan (“the 2004 Plan”). The 2004 Plan provided for the grant of incentive stock options (“ISOs”), as well as nonstatutory options. The Board of Directors administers the 2004 Plan and had sole discretion to grant options to purchase shares of Cynosure’s common stock.
	The Board of Directors determines the term of each option, option price, number of shares for which each option is granted, whether restrictions would be imposed on the shares subject to options and the rate at which each option is exercisable. The exercise price for options granted is determined by the Board of Directors, except that for ISOs, the exercise price could not be less than the fair market value per share of the underlying common stock on the date granted (110% of fair market value for ISOs granted to holders of more than 10% of the voting stock of Cynosure). The term of the options is set forth in the applicable option agreement, except that in the case of ISOs, the option term cannot exceed ten years. Options granted under the 2004 Plan vested either (i) over a 48-month period at the rate of 25% after the first year and 6.25% each quarter thereafter until fully vested or (ii) over a vesting period determined by the Board of Directors. As of December 31, 2014, there were no shares available for future grant under the 2004 Plan.
	2005 Stock Incentive Plan
	In August 2005, the Board of Directors adopted the 2005 Stock Incentive Plan (“the 2005 Plan”), which was approved by Cynosure’s stockholders in December 2005. The 2005 Plan provided for the grant of ISOs, as well as nonstatutory options and RSUs. The Board of Directors administers the 2005 Plan and has sole discretion to grant options to purchase shares of Cynosure’s common stock and RSUs.
	The Board of Directors determines the term of each option and RSU, option price, number of shares for which each option and RSU is granted, whether restrictions would be imposed on the shares subject to options and the rate at which each option is exercisable. The exercise price for options granted is determined by the Board of Directors, except that for ISOs, the exercise price could not be less than the fair market value per share of the underlying common stock on the date granted (110% of fair market value for ISOs granted to holders of more than 10% of the voting stock of Cynosure). The term of the options and RSUs is set forth in the applicable option agreement, except that in the case of ISOs, the option term cannot exceed ten years. At December 31, 2014 the number of shares of Class A common stock reserved for issuance under the 2005 Plan is 5,588,369 shares. Options granted under the Plan vest either (i) over a 36-month period at the rate of 8.33% each quarter until fully vested or (ii) over a vesting period determined by the Board of Directors. RSUs granted to employees under the 2005 Plan vest over a 36-month period at the rate of 33% each year until fully vested, and RSUs granted to non-employee directors under the 2005 Plan vest over a 12-month period at the rate of 25% each quarter until fully vested. As of December 31, 2014, there were 1,417,338 shares available for future grant under the 2005 Plan.

	Stock Options
	Stock option activity under the 2004 Plan and the 2005 Plan is as follows:


		Number of			Exercise Price		Weighted-		Weighted-		Aggregate
		Options			Range		Average		Average		Intrinsic
							Exercise		Remaining		Value
							Price		Contractual		(in thousands)
									Life
	Vested		1,596,565		$	3.00 - $36.94		16.93			$	16,061
	Unvested		707,301			9.56 - 28.68		23.06				2,985

	Outstanding, December 31, 2013		2,303,866		$	3.00 - $36.94	$	18.81		6.51 years	$	19,046
	Granted		854,180			18.94 - 31.22		27.5				1,234
	Exercised		(587,359	)		3.00 - 28.68		13.88				9,116
	Forfeited		(82,199	)		10.15 - 29.40		27.73				91

	Outstanding, December 31, 2014		2,488,488		$	4.50 - $36.94	$	22.66		6.78 years	$	13,713

	Vested		1,704,455			4.50 - 36.94		20.62		5.78 years		12,417
	Unvested		784,033			11.76 - 31.22		27.09		8.96 years		1,296

	Vested or expected to vest, December 31, 2014		2,451,983		$	4.50 - $36.94	$	22.58		6.75 years	$	13,670

	Exercisable, December 31, 2014		1,704,455		$	4.50 - $36.94	$	20.62		5.78 years	$	12,417
	Restricted Stock Units
	RSU activity under the 2005 Plan is as follows:


		Number of			Grant Date Fair		Weighted-		Weighted-		Aggregate
		RSUs			Value		Average		Average		Intrinsic
					Range		Grant		Remaining		Value
							Date Fair		Contractual		(in thousands)
							Value		Life
	Outstanding, December 31, 2013		—		$	—	$	—		—	$	—
	Granted		88,340			21.11 - 29.40		25.32				2,422
	Exercised		(32,957	)		21.11 - 29.40		23.93				811
	Forfeited		—			—		—				—

	Outstanding, December 31, 2014		55,383		$	21.11 - $29.40	$	26.14		9.22 years	$	1,518

	Vested		—			—		—		—		—
	Unvested		55,383			21.11 - 29.40		26.14		9.22 years		1,518

	Vested or expected to vest, December 31, 2014		53,700		$	21.11 - $29.40	$	26.04		9.22 years	$	1,472

	Exercisable, December 31, 2014		—		$	—	$	—		—	$	—

	The following table summarizes the RSU grant and unrecognized compensation expense for the year ended December 2014. RSUs granted during the year ended December 31, 2014 to employees vest annually over a three-year period; Cynosure is recognizing related compensation expense on a straight-line basis over the three-year period. RSUs granted during the year ended December 31, 2014 to non-employee directors vest quarterly over a one-year period; Cynosure is recognizing related compensation expense on a straight-line basis over the one-year period.


		Number of RSUs			Unrecognized		Weighted
		Granted			Stock-based		Average Period
					Compensation at		for Recognition
					December 31,		of Unrecognized
					2014		Compensation
		(in thousands)
As of December 31, 2014			88,340		$	1,278		1.3 years

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes
	Income (loss) before income tax (benefit) provision consists of the following:


			2014				2013				2012
			(In thousands)
	Domestic		$	15,424			$	(8,633	)		$	10,344
	Foreign			2,914				3,096				2,381

	Total		$	18,338			$	(5,537	)		$	12,725

	The (benefit) provision for income taxes consists of:


			2014				2013				2012
			(In thousands)
	Current:
	Federal		$	734			$	732			$	1,382
	State			577				214				128
	Foreign			1,306				890				606

	Total current			2,617				1,836				2,116
	Deferred:
	Federal			(13,032	)			(5,406	)			152
	State			(1,398	)			(304	)			—
	Foreign			(1,187	)			(16	)			(504	)

	Total deferred			(15,617	)			(5,726	)			(352	)

			$	(13,000	)		$	(3,890	)		$	1,764


	A reconciliation of the federal statutory rate to Cynosure’s effective tax rate is as follows for the years ended December 31:


			2014				2013				2012
	Income tax provision at federal statutory rate:			35	%			35	%			35	%
	Increase (decrease) in tax resulting from -
	State taxes, net of federal benefit			0.8				(3.1	)			0.7
	Nondeductible expenses			7.2				(11.9	)			2.1
	Tax-exempt interest income			(0.2	)			0.5				(0.3	)
	Effect of foreign taxes			(0.6	)			2.7				(1.8	)
	Stock-based compensation			0.1				(0.1	)			(0.9	)
	Research and development credit			(2.7	)			25.8				—
	Change in uncertain tax positions			(0.3	)			4.8				2.5
	Change in valuation allowance			(108.8	)			162				(20.5	)
	Change in control payments			1.6				(128.8	)			—
	Transaction costs			—				(13.6	)			—
	Other			(3.0	)			(3.1	)			(2.9	)

	Effective income tax rate			(70.9	)%			70.2	%			13.9	%

	In 2014, Cynosure recorded an income tax benefit of $13.0 million, representing an effective tax rate of (71)%. The difference between the statutory tax rate and the effective tax rate was primarily attributable to a tax benefit of $19.0 million for the release of substantially all of the valuation allowance maintained against the net U.S. deferred tax asset. In addition, Cynosure recorded a tax benefit of $0.9 million related to the release of valuation allowances against the net deferred tax assets of Cynosure Japan, Palomar Australia and Palomar Spain. Excluding the valuation allowance releases, the tax provision for the year ended December 31, 2014 would have been $6.9 million. Other factors resulting in differences between the statutory tax rate and effective tax rate are the jurisdictional mix of earnings, valuation allowance maintained against certain foreign deferred tax assets, non-deductible expenses and tax credits.
	Cynosure considered several sources of taxable income in making its valuation allowance assessments including taxable income in carryback years, future reversals of existing taxable temporary differences, tax planning strategies and forecasted future income. The U.S. consolidated tax group was profitable in 2014 and 2012 (and its book loss in 2013 was driven by costs associated with the acquisition of Palomar, a significant portion of which were permanently non-deductible for tax purposes). Cynosure is in a significant cumulative three year book income position in the U.S. with projections of strong future profitability. Cynosure Japan, Palomar Australia and Palomar Spain are all in cumulative book income positions with projected future profitability.

	Significant components of Cynosure’s deferred tax assets and liabilities as of December 31, 2014 and 2013 are as follows:


			2014				2013
			(In thousands)
	Deferred tax assets:
	Accrued expenses and reserves		$	7,917			$	9,747
	Domestic net operating loss & tax credit carry-forwards			15,873				19,925
	Foreign net operating loss carry-forwards			2,011				2,022
Stock-based compensation			6,829				6,020
Capital leases			5,955				5,472
Other deferred tax assets			2,368				1,636

Gross deferred tax assets		$	40,953			$	44,822
Valuation allowance			(977	)			(19,186	)

Total deferred tax assets (after valuation allowance)		$	39,976			$	25,636
Long-term deferred tax liabilities:
Intangible assets		$	(15,358	)		$	(18,227	)
Fixed assets			(7,135	)			(5,463	)
Other deferred tax liabilities			(847	)			(534	)

Total long-term deferred tax liabilities		$	(23,340	)		$	(24,224	)
Net deferred tax assets		$	16,636			$	1,412

Cynosure’s valuation allowance decreased by a net amount of $18.2 million during 2014. The valuation allowance increased from 2013 as a result of the impact of final purchase accounting entries related to the Palomar acquisition and current year losses in jurisdictions in which Cynosure maintains a full valuation allowance. The valuation allowance decreased by $19.0 million as a result of the release of substantially all of the valuation allowance maintained against its net U.S. deferred tax asset. In addition, the valuation allowance decreased by $0.9 million related to the release of valuation allowances against the net deferred tax assets of Cynosure Japan, Palomar Australia and Palomar Spain. As of December 31, 2014, a full valuation allowance is maintained on the net deferred tax assets of its subsidiary in Mexico as well as Palomar Japan and Palomar Germany.
At December 31, 2014, Cynosure has domestic federal net operating loss carryforwards of approximately $29.8 million, state net operating loss carryforwards of $0.5 million, federal tax credit carryforwards of $6.9 million and state tax credit carryforwards of $2.1 million that are available to reduce future taxable income. Utilization of the net operating losses and tax credits acquired as a result of the Palomar acquisition are subject to an annual limitation due to the ownership change limitations set forth under Internal Revenue Code Sections 381, 382 and 383. At December 31, 2014, none of the federal net operating loss carryforwards, $0.2 million of the state net operating loss carryforwards, $2.0 million of the federal tax credit carryforwards and $0.1 million of the state tax credit carryforwards relate to excess stock based compensation tax benefits for which the benefit will be recorded to additional paid-in capital when recognized. The federal and state net operating losses begin to expire in 2021 and 2018, respectively. The federal and state tax credits begin to expire in 2018 and 2016, respectively.
At December 31, 2014, Cynosure has foreign net operating losses of approximately $6.0 million in Germany, Mexico, Japan, France and Spain that are available to reduce future income. Foreign net operating losses in Germany and France do not expire. Mexican and Japanese net operating losses will begin to expire in 2019. Spanish net operating losses will begin to expire in 2029. Income taxes have not been provided on the undistributed earnings of foreign subsidiaries of approximately $14.0 million, because such earnings are considered to be indefinitely reinvested in the business. The accumulated earnings in the foreign subsidiaries are primarily utilized to fund working capital requirements as Cynosure’s subsidiaries continue to expand their operations, to service existing obligations and to fund future foreign acquisitions. Cynosure does not believe it is practicable to estimate the amount of income taxes payable on the earnings that are indefinitely reinvested in foreign operations.

ASC 740 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements by prescribing a minimum recognition threshold and measurement of a tax position taken or expected to be taken in a tax return.
The aggregate changes in gross unrecognized tax benefits during the years ended December 31, 2014, 2013 and 2012 were as follows (in thousands):


		2014				2013				2012
Balance at beginning of year		$	1,701			$	586			$	—
Increases for tax positions taken during current period			—				76				398
Increases for tax positions taken in prior periods			—				—				188
Increases for acquired tax positions taken in prior periods			—				1,625				—
Decreases for acquired tax positions within measurement window			(815	)			—				—
Decreases for tax positions taken in prior periods			(76	)			(398	)			—
Decreases for lapse in statutes			—				(188	)			—

Balance at end of year		$	810			$	1,701			$	586

At December 31, 2014, Cynosure had gross tax-effected unrecognized tax benefits of $0.8 million of which the entire amount, if recognized, would favorably impact the effective tax rate. At December 31, 2013, Cynosure had gross tax-effected unrecognized tax benefits of $1.7 million of which $0.1 million, if recognized, would favorably impact the effective tax rate. At December 31, 2013, Cynosure had gross tax-affected unrecognized tax benefits of $0.6 million of which $0.3 million, if recognized, would favorably impact the effective tax rate. Cynosure classifies interest and penalties related to income taxes as a component of its provision for income taxes, and the amount of interest and penalties recorded as of December 31, 2014 and 2013 in the statements of operations and balance sheet was immaterial. Cynosure does not expect any material changes in the amounts of unrecognized tax benefits over the next 12 months.
Cynosure files income tax returns in the U.S. federal jurisdiction, and in various state and foreign jurisdictions. Cynosure is no longer subject to U.S. federal tax examinations for years prior to 2011. With few exceptions, Cynosure is no longer subject to U.S. state and local income tax examinations by tax authorities for years before 2010. Additionally, certain non-U.S. jurisdictions are no longer subject for income tax examinations by tax authorities for years before 2010.

401k_Plan

401(k) Plan	12 Months Ended
401(k) Plan	Dec. 31, 2014
Postemployment Benefits [Abstract]
401(k) Plan	12. 401(k) Plan
401(k) Plan	Cynosure sponsors the Cynosure 401(k) defined contribution plan. Participation in the plan is available to all employees of Cynosure who meet certain eligibility requirements. The 401(k) is qualified under Section 401(k) of the Internal Revenue Code, and is subject to contribution limitations as set annually by the Internal Revenue Service. Employer matching contributions are at Cynosure’s discretion. Cynosure’s contributions to this plan totaled approximately $0.9 million, $0.6 million and $0.4 million for the years ended December 31, 2014, 2013 and 2012, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	13. Commitments and Contingencies
	Lease Commitments
	Cynosure leases the land portion of its U.S. operating facility and certain foreign facilities under noncancelable operating lease agreements expiring through May 2027. These leases are non-cancellable and typically contain renewal options. Certain leases contain rent escalation clauses for which Cynosure recognizes the expense on a straight-line basis. Rent expense for the years ended December 31, 2014, 2013 and 2012 was approximately $3.2 million, $2.4 million and $2.1 million, respectively.

	Cynosure leases the buildings portion of its U.S. operating facility and certain equipment and vehicles under capital lease agreements with payments due through May 2027. Commitments under Cynosure’s lease arrangements are as follows (in thousands):


		Operating		Capital
		Leases		Leases
	2015	$	2,073	$	164
	2016		1,966		2,194
	2017		1,948		2,572
	2018		1,895		2,520
	2019		1,411		2,514
	Thereafter		2,747		20,166

	Total minimum lease payments	$	12,040	$	30,130

	Less amount representing interest				(13,905	)

	Present value of obligations under capital leases			$	16,225
	Current portion of capital lease obligations				137

	Capital lease obligations, net of current portion			$	16,088

	Contingencies
	Cynosure continually assessed litigation to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss, which could be estimated. In accordance with the FASB’s guidance on accounting for contingencies, Cynosure accrues for all direct costs associated with the estimated resolution of contingencies at the earliest date at which it is deemed probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely, Cynosure accrues the minimum amount of the range. In cases where Cynosure believes that a reasonably possible loss exists, Cynosure discloses the facts and circumstances of the litigation, including an estimable range, if possible. In management’s opinion, Cynosure is not currently involved in any legal proceedings, which, individually or in the aggregate, could have a material effect on Cynosure’s financial statements. Cynosure believes that contingent losses associated with any current litigation were remote as of December 31, 2014 and at the time of the filing, and as such, Cynosure has not recorded or disclosed any material loss contingencies.

Summary_Selected_Quarterly_Fin

Summary Selected Quarterly Financial Data (Unaudited)	12 Months Ended
Summary Selected Quarterly Financial Data (Unaudited)	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Summary Selected Quarterly Financial Data (Unaudited)	14. Summary Selected Quarterly Financial Data (Unaudited)
	The following table sets forth certain unaudited consolidated quarterly statement of operations data for the eight quarters ended December 31, 2014. This information is unaudited, but in the opinion of management, it has been prepared on the same basis as the audited consolidated financial statements and all necessary adjustments, consisting only of normal recurring adjustments, have been included in the amounts stated below to state fairly the unaudited consolidated quarterly results of operations. The results of operations for any quarter are not necessarily indicative of the results of operations for any future period.


			Quarter Ended
			March 31,		June 30,			Sept. 30,			Dec. 31,
			2014		2014			2014			2014
			(In thousands, except per share data)
	Revenues		$	62,004	$	72,573		$	71,530		$	86,262
	Gross profit		$	35,395	$	40,693		$	40,298		$	48,852
	Income from operations		$	1,346	$	6,398		$	5,250		$	8,266
	Net income(1)		$	689	$	4,575		$	3,074		$	23,000
	Basic net income per share(1)		$	0.03	$	0.21		$	0.14		$	1.06
	Diluted net income per share(1)		$	0.03	$	0.2		$	0.14		$	1.05

	-1	Net income and basic and diluted net income per share data for the quarter ended December 31, 2014 include an income tax benefit of $19.9 million resulting from the release of substantially all of the valuation allowance maintained against Cynosure’s net U.S. deferred tax asset.


			Quarter Ended
			March 31,		June 30,			Sept. 30,			Dec. 31,
			2013		2013			2013			2013
			(In thousands, except per share data)
	Revenues		$	40,690	$	50,091		$	60,692		$	74,537
	Gross profit		$	23,687	$	27,787		$	34,134		$	44,672
	Income (loss) from operations		$	1,988	$	(14,639	)	$	(1,426	)	$	8,250
	Net income (loss)		$	1,239	$	(8,954	)	$	(1,281	)	$	7,349
	Basic net income (loss) per share		$	0.08	$	(0.54	)	$	(0.06	)	$	0.33
	Diluted net income (loss) per share		$	0.07	$	(0.54	)	$	(0.06	)	$	0.33

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2014
Accounting Policies [Abstract]
Management Estimates	Management Estimates
Management Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosures at the date of the financial statements and during the reporting period. Components particularly subject to estimation include the allowance for doubtful accounts, inventory reserves, intangible assets, impairment analysis of goodwill and intangibles, deferred tax assets, liabilities and valuation allowances, fair value of stock options and investments and accrued warranties. On an ongoing basis, management evaluates its estimates. Actual results could differ from these estimates.
Principles of Consolidation	Principles of Consolidation
Principles of Consolidation	The accompanying consolidated financial statements include the accounts of Cynosure, Inc. and its wholly owned subsidiaries: Cynosure Securities Corporation, Palomar Medical Products, LLC, Cynosure Mexico, Cynosure Langen GmbH, Cynosure Hamburg GmbH, S.A.R.L. Cynosure France, Cynosure Maroc SARL, Cynosure UK LTD, Cynosure Spain S.L., Cynosure B.V., Cynosure K.K., Suzhou Cynosure Medical Devices Company Ltd., Cynosure Korea Limited, Cynosure Pty Ltd., and Palomar Japan K.K. All intercompany balances and transactions have been eliminated.
Reclassification	Reclassification
Reclassification	Certain amounts in prior years’ financial statements have been reclassified to conform to the current year’s presentation within the consolidated statements of operations.
Cash, Cash Equivalents, Short and Long-Term Marketable Securities	Cash, Cash Equivalents, Short and Long-Term Marketable Securities
	Cynosure considers all short-term, highly liquid investments with original maturities at the time of purchase of 90 days or less to be cash equivalents. Cynosure accounts for short and long-term marketable securities as available-for-sale in accordance with Accounting Standards Codification (“ASC”) 320, Investments—Debt and Equity Securities Topic. Under ASC 320, securities purchased to be held for indefinite periods of time and not intended at the time of purchase to be held until maturity are classified as available-for-sale securities. ASC 320 requires Cynosure to recognize all marketable securities on the consolidated balance sheets at fair value. Cynosure’s marketable securities are stated at fair value based on quoted market prices. Adjustments to the fair value of marketable securities that are classified as available-for-sale are recorded as increases or decreases, net of income taxes, within accumulated other comprehensive loss in shareholders’ equity. The amortized cost of marketable debt securities is adjusted for amortization of premiums and discounts to maturity computed under the effective interest method. The cost of securities sold is determined by the specific identification method. Cynosure continually evaluates whether any marketable securities have been impaired and, if so, whether such impairment is temporary or other than temporary.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	Cynosure’s financial instruments consist of cash, cash equivalents, short and long-term marketable securities, accounts receivable and capital leases. Cynosure’s estimate of fair value for financial instruments, other than marketable securities, which are carried at fair value, approximates their carrying value at December 31, 2014 and 2013.
	ASC 820, Fair Value Measurement Topic, applies to all financial assets and financial liabilities that are being measured and reported on a fair value basis, establishes a framework for measuring fair value of assets and liabilities and expands disclosures about fair value measurements.
Concentration of Credit Risk	Concentration of Credit Risk
	Financial instruments that subject Cynosure to credit risk consist primarily of cash and cash equivalents, short and long-term marketable securities and accounts receivable. Cynosure places cash and cash equivalents and short and long-term marketable securities in established financial institutions. Cynosure has no significant off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements. Cynosure’s accounts receivable balance, net of allowance for doubtful accounts, was $42.5 million as of December 31, 2014, compared with $36.6 million as of December 31, 2013. The allowance for doubtful accounts as of December 31, 2014 and 2013 was $2.9 million and $1.8 million, respectively. Cynosure maintains an allowance for doubtful accounts based upon the aging of its receivable balances, known collectibility issues and Cynosure’s historical experience with losses. Cynosure works to mitigate bad debt exposure through its credit evaluation policies, reasonably short payment terms and geographical dispersion of sales. Losses from bad debt have historically been within management’s estimates. Cynosure’s revenue includes export sales to foreign companies located principally in Europe, the Asia/Pacific region and the Middle East. Cynosure obtains letters of credit for foreign sales that the Company considers to be at risk.
	No customer accounted for 10% or greater of revenue during 2014, 2013 or 2012. No customer accounted for 10% or greater of accounts receivable as of December 31, 2014 or 2013. Accounts receivable allowance activity consisted of the following for the years ended December 31:


		2014			2013			2012
		(In thousands)
	Balance at beginning of year	$	1,803		$	2,043		$	1,872
	Additions		2,373			1,058			591
	Deductions		(1,227	)		(1,298	)		(420	)

	Balance at end of year	$	2,949		$	1,803		$	2,043

Inventory	Inventory
	Cynosure states all inventories at the lower of cost or market, determined on a first-in, first-out method. Inventory includes material, labor and overhead and consists of the following:


		December 31,
		2014			2013 (recast)
		(In thousands)
	Raw materials	$	16,875		$	16,900
	Work in process		3,526			2,316
	Finished goods		38,917			31,035

		$	59,318		$	50,251

	Included in finished goods are lasers used for demonstration purposes. Cynosure’s policy is to include demonstration lasers as inventory for a period of up to one year after being used by the sales force at which time the demonstration lasers are either sold or transferred to fixed assets at the lower of cost or market and depreciated over their estimated useful life of three years. Similar to any other finished goods in inventory, Cynosure accounts for such demonstration inventory in accordance with the policy for excess and obsolescence review of Cynosure’s entire inventory.
	Cynosure’s excess and obsolescence reserve policy is to establish inventory reserves when conditions exist that suggest that inventory may be in excess of anticipated demand or is obsolete based upon assumptions about future demand for products and market conditions. Cynosure regularly evaluates the ability to realize the value of inventory based on a combination of factors including the following: historical usage rates, forecasted sales or usage, product end of life dates, estimated current and future market values and new product introductions.
	Cynosure purchases raw material components as well as certain finished goods from sole source suppliers. A delay in the production capabilities of these vendors could cause a delay in Cynosure’s manufacturing, and a possible loss of revenues, which would adversely affect operating results.
Property and Equipment	Property and Equipment
Property and Equipment	Property and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Assets under capital leases and leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the respective lease term. Included in property and equipment are certain lasers that are used for demonstration purposes. Maintenance and repairs are charged to expense as incurred. Cynosure continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. Cynosure evaluates the realizability of its long-lived assets based on profitability and cash flow expectations for the related asset. Any write-downs are treated as permanent reductions in the carrying amount of the assets. Based on this evaluation, Cynosure believes that, as of each of the balance sheet dates presented, none of Cynosure’s long-lived assets were impaired.
Intangible Assets	Intangible Assets
Intangible Assets	Cynosure capitalizes and includes in intangible assets the costs of developed technology and patents, customer relationships, trade names and business licenses. Intangible assets are recorded at fair value and stated net of accumulated amortization and impairments. Cynosure amortizes its intangible assets that have finite lives using either the straight-line or accelerated method, based on the useful life of the asset over which it is expected to be consumed utilizing expected undiscounted future cash flows. Amortization is recorded over the estimated useful lives ranging from five to 23 years. Cynosure evaluates the realizability of its definite lived intangible assets whenever events or changes in circumstances or business conditions indicate that the carrying value of these assets may not be recoverable based on expectations of future undiscounted cash flows for each asset group. If the carrying value of an asset or asset group exceeds its undiscounted cash flows, Cynosure estimates the fair value of the assets, generally utilizing a discounted cash flow analysis based on the present value of estimated future cash flows to be generated by the assets using a risk-adjusted discount rate. To estimate the fair value of the assets, Cynosure uses market participant assumptions pursuant to ASC 820, Fair Value Measurements. If the estimate of an intangible asset’s remaining useful life is changed, Cynosure will amortize the remaining carrying value of the intangible asset prospectively over the revised useful life.
Goodwill	Goodwill
	Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a business combination. Cynosure does not amortize its goodwill, but instead tests for impairment at least annually and more frequently whenever events or changes in circumstances indicate that the fair value of the asset may be less than its carrying value of the asset. Cynosure’s annual test for impairment occurs on the first day of its fourth quarter.
	Cynosure has adopted Accounting Standards Update (“ASU”) 2011-08 Intangibles—Goodwill and Other, an amendment to ASC 350, which updates how an entity will evaluate its goodwill for impairment. The guidance provides entities an option to perform a “qualitative” assessment to determine whether further impairment testing is necessary. If further testing is required, the test for impairment continues with the two step process. The first step compares the carrying amount of the reporting unit to its estimated fair value (Step 1). To the extent that the carrying value of the reporting unit exceeds its estimated fair value, a second step is performed, wherein the reporting unit’s carrying value is compared to the implied fair value (Step 2). To the extent that the carrying value exceeds the implied fair value, impairment exists and must be recognized.
	Cynosure has one reporting unit for goodwill impairment testing and has performed a qualitative assessment on that reporting unit. As a result of this assessment, the Company determined that goodwill is not impaired as of December 31, 2014 and 2013.
Revenue Recognition and Deferred Revenue	Revenue Recognition and Deferred Revenue
	Cynosure generates revenue from the sale of non-invasive and minimally invasive light-based aesthetic treatment applications, as well as radiofrequency energy based surgical and aesthetic applications. Cynosure offers service and warranty contracts in connection with these sales.
	Cynosure recognizes revenue from sales of aesthetic treatment systems and parts and accessories in accordance with the Revenue Recognition Topic ASC 605-10-S99. Cynosure recognizes revenue from sales of its treatment systems and parts and accessories upon delivery, provided there are no uncertainties regarding customer acceptance, there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collectibility of the related receivable is reasonably assured. Revenues from the sales of service and warranty contracts are deferred and recognized on a straight-line basis over the contract period as services are provided. Payments received by Cynosure in advance of product delivery or performance of services are deferred until earned.
	Cynosure recognizes royalty revenues when it can reliably estimate such amounts and collectability is reasonably assured. As such, Cynosure recognizes royalty revenues in the quarter reported to the Company by its licensees, or one quarter following the quarter in which sales by Cynosure’s licensees occurred. Royalty revenues also include amounts due from settlements with licensees for back-owed royalties from prior periods. These settlement amounts are considered revenue, when collectability is reasonably assured, because they constitute Cynosure’s ongoing major or central operations.

	In December 2013, Cynosure completed a comprehensive settlement agreement with Tria Beauty, Inc. (“Tria”) which ended the patent infringement litigation between Tria and Palomar Medical Technologies, Inc. (“Palomar”). Under the agreement, Cynosure is entitled to receive $10.0 million plus future royalty payments. Cynosure will pay approximately $2.0 million of this revenue to Massachusetts General Hospital (“MGH”) under an exclusive license agreement between Palomar and MGH, which will be recorded as cost of revenues within Cynosure’s consolidated statement of operations. Cynosure recognized $3.0 million and $4.0 million of this revenue in the years ended December 31, 2014 and 2013, respectively which is recorded as royalty revenues within Cynosure’s consolidated statement of operations. Cynosure recognized $0.8 million and $1.0 million in cost of revenues in the years ended December 31, 2014 and 2013, respectively, related to this revenue.
	Multiple-element arrangements are evaluated in accordance with the principles of ASU 2009-13, Revenue Recognition Topic—Multiple Element Arrangements and Cynosure allocates revenue among the elements based upon each element’s relative fair value.
	In accordance with the provisions of ASC 605-45, Revenue Recognitions Topic—Principal Agent Considerations, Cynosure records shipping and handling costs billed to its customers as a component of revenue, and the underlying expense as a component of cost of revenue. Shipping and handling costs included as a component of revenue totaled approximately $1.0 million, $0.6 million, and $0.4 million for the years ended December 31, 2014, 2013 and 2012, respectively. Shipping and handling costs included as a component of cost of revenue totaled $1.1 million, $0.6 million and $0.5 million for the years ended December 31, 2014, 2013 and 2012, respectively.
	Cynosure collects sales tax from its customers on product sales for which the customer is not tax exempt and remits such taxes to the appropriate governmental authorities. Cynosure presents its sales taxes on a net basis; therefore, these taxes are excluded from revenues. Cynosure records medical device costs billed to its customers as a component of revenue and the underlying expense as a component of cost of revenue.
Cost of Revenues	Cost of Revenues
Cost of Revenues	Cynosure’s cost of revenues consist primarily of material, labor and manufacturing overhead expenses and includes the cost of components and subassemblies supplied by third party suppliers. Cost of revenues also includes royalties incurred on certain products sold by Cynosure and its licensees, costs incurred in connection with Cynosure’s efforts to litigate or settle additional third-party license agreements, amortization expense related to developed technology and patents intangible assets, service and warranty expenses, as well as salaries and personnel-related expenses, including stock-based compensation, for Cynosure’s operations management team, purchasing and quality control.
Product Warranty Costs	Product Warranty Costs
	Cynosure typically provides a one-year parts and labor warranty on end-user sales of lasers. Distributor sales generally include a one-year warranty on parts only. Estimated future costs for initial product warranties are provided for at the time of revenue recognition. The following table sets forth activity in the accrued warranty account, which is a component of accrued expenses in the consolidated balance sheets:


		Years Ended December 31,
		2014			2013			2012
		(In thousands)
	Balance at beginning of year	$	6,651		$	3,415		$	3,171
	Warranty provision related to new sales		15,104			9,114			4,641
	Warranty provision assumed from acquisitions		—			1,422			—
	Costs incurred		(13,637	)		(7,300	)		(4,397	)

	Balance at end of year	$	8,118		$	6,651		$	3,415

Research and Development	Research and Development
Research and Development	Research and development costs consist of salaries and other personnel-related expenses, including stock-based compensation, of employees primarily engaged in research, development and engineering activities and materials used and other overhead expenses incurred in connection with the design and development of Cynosure’s products and from time to time expenses associated with collaborative research agreements that the Company may enter into. These costs are expensed as incurred.
Advertising Costs	Advertising Costs
Advertising Costs	Cynosure expenses advertising costs as incurred. Advertising costs totaled $1.2 million, $1.1 million and $0.6 million for the years ended December 31, 2014, 2013 and 2012, respectively.
Foreign Currency Translation	Foreign Currency Translation
Foreign Currency Translation	The financial statements of Cynosure’s foreign subsidiaries are translated from local currency into U.S. dollars using the current exchange rate at the balance sheet date for assets and liabilities, and the average exchange rate prevailing during the period for revenue and expenses. The functional currency for Cynosure’s foreign subsidiaries is considered to be the local currency for each entity and, accordingly, translation adjustments for these subsidiaries are included in accumulated other comprehensive loss within stockholders’ equity. Certain intercompany and third party foreign currency-denominated transactions generated foreign currency remeasurement (losses) gains of approximately $(1.6 million), $0.3 million and $0.4 million during 2014, 2013 and 2012, respectively, which are included in other (expense) income, net, in the consolidated statements of operations.
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss
	Changes to accumulated other comprehensive loss during the year ended December 31, 2014 were as follows (in thousands):


		Unrealized			Translation			Accumulated
		Loss on			Adjustment			Other
		Marketable						Comprehensive
		Securities, net						Loss
		of taxes
	Balance—December 31, 2013	$	36		$	(1,535	)	$	(1,499	)
	Current period other comprehensive loss		(46	)		(2,318	)		(2,364	)

	Balance—December 31, 2014	$	(10	)	$	(3,853	)	$	(3,863	)
Stock-Based Compensation	Stock-Based Compensation
	Cynosure follows the fair value recognition provisions of ASC 718, Stock Compensation Topic. This guidance requires share-based payments to employees, including grants of employee stock options and restricted stock units (“RSUs”), to be recognized in the statement of operations based on their fair values at the date of grant. Cynosure expenses the fair value of share-based payments over the service period. ASC 718 requires companies to utilize an estimated forfeiture rate when calculating the expense for the period. Accordingly, Cynosure reviews its actual forfeiture rates and periodically aligns its stock compensation expense with the share-based payments that are vesting. Cynosure recorded stock-based compensation expense of $7.1 million, $3.7 million and $2.9 million for the years ended December 31, 2014, 2013 and 2012, respectively. As of both December 31, 2014 and 2013, Cynosure had $23,000 of stock-based compensation expense capitalized as a part of inventory.

	Total stock-based compensation expense was recorded to cost of revenues and operating expenses based upon the functional responsibilities of the individual holding the respective share-based payments, as follows:


		Years Ended December 31,
		2014			2013			2012
		(In thousands)
	Cost of revenues	$	292		$	174		$	127
	Sales and marketing		1,934			1,090			857
	Research and development		1,007			594			495
	General and administrative		3,880			1,830			1,431

	Total stock-based compensation expense	$	7,113		$	3,688		$	2,910

	As of December 31, 2014, there was $10.1 million of unrecognized compensation expense related to non-vested share awards that is expected to be recognized on a straight-line basis over a weighted average period of 1.6 years. Cash received from option exercises was $8.2 million, $2.7 million and $7.2 million during the years ended December 31, 2014, 2013 and 2012, respectively.
	Cynosure granted 854,180, 617,510 and 405,790 stock options during the years ended December 31, 2014, 2013 and 2012, respectively. Cynosure uses the Black-Scholes option pricing model to determine the weighted average fair value of options. The weighted average fair value of the options granted during the years ended December 31, 2014, 2013 and 2012 was $10.50, $10.25 and $9.23, respectively, using the following assumptions:


		Years Ended December 31,
		2014		2013	2012
	Risk-free interest rate	1.41% - 1.80%		0.33% - 1.49%	0.61% - 0.86%
	Expected dividend yield	—		—	—
	Expected term	4.6 years		2 years - 4.8 years	5.8 years
	Expected volatility	43% - 44%		44% - 56%	56% - 57%
	Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. Cynosure’s estimated expected stock price volatility is based on its own historical volatility for the 2014, 2013 and 2012 periods. Cynosure’s expected term of options granted during the years ended December 31, 2014 and 2013 represents the weighted average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and Cynosure’s historical exercise patterns. Cynosure’s expected term of options granted during the year ended December 31, 2012 was derived from the simplified method described in ASC 718-10-S99. The risk-free rate for the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The dividend yield of zero is based on the fact that Cynosure has never paid cash dividends and has no present intention to pay cash dividends.
	Cynosure granted 44,840 RSUs during the year ended December 31, 2014 to employees at a fair market value of its common stock on the date of grant and which vest annually over a three-year period. Cynosure is recognizing related compensation expense on a straight-line basis over the three-year period.
	Cynosure granted 43,500 RSUs during the year ended December 31, 2014 to non-employee directors at a fair market value of its common stock on the date of grant and which vest quarterly over a one-year period. Cynosure is recognizing related compensation expense on a straight-line basis over the one-year period.
Interest (Expense) Income, Net	Interest (Expense) Income, net
Interest (Expense) Income, Net	Interest (expense) income consists primarily of interest charges on capital lease obligations, and interest earned on Cynosure’s short and long-term marketable securities consisting of state and municipal bonds, U.S. government agencies and treasuries, corporate obligations and commercial paper. Cynosure expects interest expense to remain consistent in 2015 as compared to 2014.
Income Taxes	Income Taxes
	Cynosure provides for income taxes in accordance with ASC 740, Accounting for Income Taxes. ASC 740 recognizes tax assets and liabilities for the cumulative effect of all temporary differences between the financial statement carrying amounts and the tax basis of assets and liabilities, and are measured using the enacted tax rates that will be in effect when these differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Cynosure considers several sources of taxable income in making its valuation allowance assessments including taxable income in carryback years, future reversals of existing taxable temporary differences, tax planning strategies and forecasted future income.
	Cynosure accounts for uncertain tax positions following the provisions of ASC 740. ASC 740 clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. ASC 740 also provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition.
Net Income (Loss) per Share	Net Income (Loss) per Share
	Basic net income (loss) per share is determined by dividing net income (loss) by the weighted average common shares outstanding during the period. Diluted net income (loss) per share is determined by dividing net income (loss) by the diluted weighted average shares outstanding during the period. Diluted weighted average shares reflect the dilutive effect, if any, of common stock options and RSUs based on the treasury stock method. For the years ended December 31, 2014, 2013 and 2012, there were no outstanding Class B shares, and Cynosure may not issue Class B shares in the future.
	The reconciliation of basic and diluted weighted average shares outstanding for the years ended December 31, 2014, 2013 and 2012 is as follows (in thousands, except per share data):


		Years Ended December 31,
		2014			2013			2012
	Net income (loss)	$	31,338		$	(1,647	)	$	10,961

	Basic weighted average common shares outstanding		21,824			19,325			13,189
	Weighted average common stock equivalents		371			—			603

	Diluted weighted average common shares outstanding		22,195			19,325			13,792

	Basic net income (loss) per share	$	1.44		$	(0.09	)	$	0.83

	Diluted net income (loss) per share	$	1.41		$	(0.09	)	$	0.79

	For the year ended December 31, 2014, approximately 0.5 million shares of Cynosure’s Class A common stock issuable pursuant to options and RSUs were excluded from the calculation of diluted weighted average common shares outstanding as their effect was antidilutive.
	For the year ended December 31, 2013, the number of basic and diluted weighted average shares outstanding was the same because any increase in the number of shares of common stock equivalents for that period would be antidilutive based on the net loss for the period. During the year ended December 31, 2013, outstanding options to purchase 1.3 million shares were excluded from the computation of diluted earnings per share because their inclusion would have been antidilutive.
	For the year ended December 31, 2012, options to purchase approximately 0.7 million shares of Cynosure’s Class A common stock were excluded from the calculation of diluted weighted average common shares outstanding as their effect was antidilutive.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
Recent Accounting Pronouncements	In May 2014, the Financial Accounting Standards Board issued guidance codified in ASC 606, Revenue Recognition—Revenue from Contracts with Customers, which amends the guidance in ASC 605, Revenue Recognition. This new revenue standard creates a single source of revenue guidance for all companies in all industries and is more principles-based than the current revenue guidance. The new guidance must be adopted using either a full retrospective approach for all periods presented in the period of adoption or a modified retrospective approach. ASC 606 is effective for interim and annual periods beginning after December 15, 2016. Cynosure is currently evaluating the impact of the provisions of ASC 606.
Contingencies	Contingencies
Contingencies	Cynosure continually assessed litigation to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss, which could be estimated. In accordance with the FASB’s guidance on accounting for contingencies, Cynosure accrues for all direct costs associated with the estimated resolution of contingencies at the earliest date at which it is deemed probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely, Cynosure accrues the minimum amount of the range. In cases where Cynosure believes that a reasonably possible loss exists, Cynosure discloses the facts and circumstances of the litigation, including an estimable range, if possible. In management’s opinion, Cynosure is not currently involved in any legal proceedings, which, individually or in the aggregate, could have a material effect on Cynosure’s financial statements. Cynosure believes that contingent losses associated with any current litigation were remote as of December 31, 2014 and at the time of the filing, and as such, Cynosure has not recorded or disclosed any material loss contingencies.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2014
Accounting Policies [Abstract]
Accounts Receivable Allowance Activity	Accounts receivable allowance activity consisted of the following for the years ended December 31:


		2014			2013			2012
		(In thousands)
	Balance at beginning of year	$	1,803		$	2,043		$	1,872
	Additions		2,373			1,058			591
	Deductions		(1,227	)		(1,298	)		(420	)

	Balance at end of year	$	2,949		$	1,803		$	2,043

Inventories	Cynosure states all inventories at the lower of cost or market, determined on a first-in, first-out method. Inventory includes material, labor and overhead and consists of the following:


		December 31,
		2014			2013 (recast)
		(In thousands)
	Raw materials	$	16,875		$	16,900
	Work in process		3,526			2,316
	Finished goods		38,917			31,035

		$	59,318		$	50,251

Activity in the Accrued Warranty Account	The following table sets forth activity in the accrued warranty account, which is a component of accrued expenses in the consolidated balance sheets:


		Years Ended December 31,
		2014			2013			2012
		(In thousands)
	Balance at beginning of year	$	6,651		$	3,415		$	3,171
	Warranty provision related to new sales		15,104			9,114			4,641
	Warranty provision assumed from acquisitions		—			1,422			—
	Costs incurred		(13,637	)		(7,300	)		(4,397	)

	Balance at end of year	$	8,118		$	6,651		$	3,415

Changes to Accumulated Other Comprehensive Loss	Changes to accumulated other comprehensive loss during the year ended December 31, 2014 were as follows (in thousands):


		Unrealized			Translation			Accumulated
		Loss on			Adjustment			Other
		Marketable						Comprehensive
		Securities, net						Loss
		of taxes
	Balance—December 31, 2013	$	36		$	(1,535	)	$	(1,499	)
	Current period other comprehensive loss		(46	)		(2,318	)		(2,364	)

	Balance—December 31, 2014	$	(10	)	$	(3,853	)	$	(3,863	)
Summary of Stock-Based Compensation Expenses	Total stock-based compensation expense was recorded to cost of revenues and operating expenses based upon the functional responsibilities of the individual holding the respective share-based payments, as follows:


		Years Ended December 31,
		2014			2013			2012
		(In thousands)
	Cost of revenues	$	292		$	174		$	127
	Sales and marketing		1,934			1,090			857
	Research and development		1,007			594			495
	General and administrative		3,880			1,830			1,431

	Total stock-based compensation expense	$	7,113		$	3,688		$	2,910

Summary of Share-Based compensation Arrangement Fair Value Assumptions	The weighted average fair value of the options granted during the years ended December 31, 2014, 2013 and 2012 was $10.50, $10.25 and $9.23, respectively, using the following assumptions:


		Years Ended December 31,
		2014		2013	2012
	Risk-free interest rate	1.41% - 1.80%		0.33% - 1.49%	0.61% - 0.86%
	Expected dividend yield	—		—	—
	Expected term	4.6 years		2 years - 4.8 years	5.8 years
	Expected volatility	43% - 44%		44% - 56%	56% - 57%
Schedule of Reconciliation of Basic and Diluted Shares	The reconciliation of basic and diluted weighted average shares outstanding for the years ended December 31, 2014, 2013 and 2012 is as follows (in thousands, except per share data):


		Years Ended December 31,
		2014			2013			2012
	Net income (loss)	$	31,338		$	(1,647	)	$	10,961

	Basic weighted average common shares outstanding		21,824			19,325			13,189
	Weighted average common stock equivalents		371			—			603

	Diluted weighted average common shares outstanding		22,195			19,325			13,792

	Basic net income (loss) per share	$	1.44		$	(0.09	)	$	0.83

	Diluted net income (loss) per share	$	1.41		$	(0.09	)	$	0.79

Fair_Value_Tables

Fair Value (Tables)	12 Months Ended
Fair Value (Tables)	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Measurement of Fair Value Hierarchy for Financial Assets	The following table represents Cynosure’s fair value hierarchy for its financial assets (cash equivalents and marketable securities) measured at fair value as of December 31, 2014 (in thousands):


			Level 1		Level 2		Level 3		Total
	Money market funds(1)		$	1,753	$	—	$	—	$	1,753
	State and municipal bonds			—		47,744		—		47,744
	Treasuries and government agencies			—		8,486		—		8,486
	Corporate obligations and commercial paper			—		2,001		—		2,001
	Equity securities			13		—		—		13

	Total		$	1,766	$	58,231	$	—	$	59,997


	-1	Included in cash and cash equivalents at December 31, 2014.
	The following table represents Cynosure’s fair value hierarchy for its financial assets (cash equivalents and marketable securities) measured at fair value as of December 31, 2013 (in thousands):


			Level 1		Level 2		Level 3		Total
	Money market funds(1)		$	5,185	$	—	$	—	$	5,185
	State and municipal bonds(2)			—		18,133		—		18,133
	Treasuries and government agencies			—		15,028		—		15,028
	Corporate obligations and commercial paper			—		3,020		—		3,020
	Equity securities			49		—		—		49

	Total		$	5,234	$	36,181	$	—	$	41,415


	-1	Included in cash and cash equivalents at December 31, 2013.
	-2	$0.8 million included in cash and cash equivalents at December 31, 2013.

Short_and_LongTerm_Marketable_1

Short and Long-Term Marketable Securities (Tables)	12 Months Ended
Short and Long-Term Marketable Securities (Tables)	Dec. 31, 2014
Investments, Debt and Equity Securities [Abstract]
Schedule of Marketable Securities	As of December 31, 2014, Cynosure’s marketable securities consist of the following (in thousands):


		Market		Amortized		Unrealized		Unrealized
		Value		Cost		Gains		Losses
	Available-for-Sale Securities:
	Short-term marketable securities:
	State and municipal bonds	$	26,041	$	26,033	$	8	$	—
	Treasuries and government agencies		4,000		4,000		—		—
	Corporate obligations and commercial paper		2,001		2,001		—		—
	Equity securities		13		18		—		(5	)

	Total short-term marketable securities	$	32,055	$	32,052	$	8	$	(5	)

	Long-term marketable securities:
	State and municipal bonds	$	21,703	$	21,721	$	2	$	(20	)
	Treasuries and government agencies		4,486		4,500		—		(14	)

	Total long-term marketable securities	$	26,189	$	26,221	$	2	$	(34	)

	Total available-for-sale securities	$	58,244	$	58,273	$	10	$	(39	)

	Total marketable securities	$	58,244

	As of December 31, 2013, Cynosure’s marketable securities consist of the following (in thousands):


		Market		Amortized		Unrealized		Unrealized
		Value		Cost		Gains		Losses
	Available-for-Sale Securities:
	Cash equivalents:
	State and municipal bonds	$	793	$	793	$	—	$	—

	Total cash equivalents	$	793	$	793	$	—	$	—

	Short-term marketable securities:
	State and municipal bonds	$	10,552	$	10,551	$	1	$	—
	Treasuries and government agencies		15,028		15,018		10		—
	Corporate obligations and commercial paper		1,004		1,004		—		—
	Equity securities		49		8		41		—

	Total short-term marketable securities	$	26,633	$	26,581	$	52	$	—

	Long-term marketable securities:
	State and municipal bonds	$	6,788	$	6,787	$	1	$	—
	Corporate obligations and commercial paper		2,016		2,015		1		—

	Total long-term marketable securities	$	8,804	$	8,802	$	2	$	—

	Total available-for-sale securities	$	36,230	$	36,176	$	54	$	—

	Total marketable securities	$	35,437

Schedule of Available-for-Sale Debt Securities Mature	As of December 31, 2014, Cynosure’s available-for-sale debt securities mature as follows (in thousands):


				Maturities
		Total		Less Than One Year		One to Five Years		More than five years
	State and municipal bonds	$	47,744	$	26,041	$	21,703	$	—
	Treasuries and government agencies		8,486		4,000		4,486		—
	Corporate obligations and commercial paper		2,001		2,001		—		—

	Total available-for-sale debt securities	$	58,231	$	32,042	$	26,189	$	—

Acquisition_Tables

Acquisition (Tables)	12 Months Ended
Acquisition (Tables)	Dec. 31, 2014
Business Combinations [Abstract]
Estimated Fair Value of Net Assets Acquired	The following table summarizes the estimated fair value as of September 5, 2014 of the net assets acquired (in thousands):


	Purchase price:
	Cash paid	$	13,235

	Total	$	13,235

	Assets (liabilities) acquired:
	Accounts receivable		2,147
	Inventory		3,682
	Prepaid and other assets		488
	Fixed assets		612
	Intangible assets		6,800
	Goodwill		6,598
	Accounts payable		(9	)
	Accrued expenses		(2,469	)
	Deferred revenue		(454	)
	License transfer agreement		(4,160	)

	Total	$	13,235

Pro-forma Condensed Consolidated Operating Results	The following unaudited pro forma condensed consolidated operating results for the years ended December 31, 2014 and 2013 summarize the combined results of operations for Cynosure and Ellman.

		Year Ended
		December 31,
		2014			2013
	Revenue (unaudited, in thousands)	$	308,980		$	255,077
	Pre-tax income (loss) (unaudited, in thousands)	$	17,978		$	(12,261	)

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
Goodwill and Other Intangible Assets (Tables)	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Changes to Goodwill	Changes to goodwill during the year ended December 31, 2014 were as follows (in thousands):


	Balance—December 31, 2013 (recast)	$	99,237
	Ellman acquisition		6,598
	Translation adjustment		(71	)

	Balance—December 31, 2014	$	105,764

Schedule of Components of Other Intangible Assets	Other intangible assets consist of the following at December 31, 2014 and December 31, 2013 (in thousands):


		Developed			Business			Customer			Trade			Other			Total
		Technology			Licenses			Relationships			Names
		& Patents
	December 31, 2014
	Cost	$	29,240		$	384		$	19,718		$	18,390		$	1,338		$	69,070
	Translation adjustment		—			34			2			—			2			38
	Accumulated amortization		(7,840	)		(252	)		(5,818	)		(1,607	)		(8	)		(15,525	)

	Balance, December 31, 2014	$	21,400		$	166		$	13,902		$	16,783		$	1,332		$	53,583

	December 31, 2013
	Cost	$	27,510		$	384		$	15,833		$	16,930		$	1,338		$	61,995
	Translation adjustment		—			40			26			—			4			70
	Accumulated amortization		(2,216	)		(239	)		(3,662	)		(761	)		(8	)		(6,886	)

	Balance, December 31, 2013	$	25,294		$	185		$	12,197		$	16,169		$	1,334		$	55,179

Schedule of Amortization Expenses on Intangible Assets	As of December 31, 2014, amortization expense on existing definite-lived intangible assets for the next five years and beyond is as follows (table in thousands):


	2015	$	9,223
	2016		8,434
	2017		6,444
	2018		4,928
	2019		3,189
	2020 and Thereafter		20,405

	Total	$	52,623

Segment_and_Geographic_Informa1

Segment and Geographic Information (Tables)	12 Months Ended
Segment and Geographic Information (Tables)	Dec. 31, 2014
Segment Reporting [Abstract]
Schedule of Total Revenue by Geographic Destination	The following table represents total revenue by geographic destination:


		Year Ended December 31,
		2014			2013			2012
		(In thousands)
	United States	$	148,803		$	111,179		$	72,704
	Europe		50,513			39,529			28,808
	Asia/Pacific		64,651			52,574			39,991
	Other		28,402			22,728			11,990

		$	292,369		$	226,010		$	153,493

Schedule of Total Assets by Geographic Area	Total assets by geographic area are as follows:


		December 31,
		2014			2013
		(In thousands)
	United States	$	420,513		$	380,383
	Europe		23,235			21,741
	Asia/Pacific		19,182			16,437
	Eliminations		(5,206	)		(3,860	)

		$	457,724		$	414,701

Schedule of Long-Lived Assets by Geographic Area	Long-lived assets (property and equipment only) by geographic area are as follows:


		December 31,
		2014			2013
		(In thousands)
	United States	$	30,912		$	24,004
	Europe		1,656			1,326
	Asia/Pacific		1,688			1,115

		$	34,256		$	26,445

Balance_Sheet_Accounts_Tables

Balance Sheet Accounts (Tables)	12 Months Ended
Balance Sheet Accounts (Tables)	Dec. 31, 2014
Text Block [Abstract]
Property and Equipment	Property and equipment consists of the following at December 31:


			Estimated		2014			2013
			Useful		Cost			Cost
			Life
			(Years)
			(In thousands)
	Equipment			5-Mar	$	9,834		$	7,835
	Furniture and fixtures			5-Mar		3,008			2,698
	Computer equipment and software			3		5,095			5,047
	Leased equipment			4-Mar		1,625			1,660
	Leased buildings			14		13,327			13,327
	Leasehold improvements			5		12,611			2,898
	Demonstration equipment			3		20,246			24,094
	Construction in-progress					42			495

						65,788			58,054
	Less: Accumulated depreciation and amortization					(31,532	)		(31,609	)

					$	34,256		$	26,445

Accrued Expenses	Accrued expenses consist of the following at December 31:


			2014		2013
			(In thousands)
	Accrued payroll and payroll taxes		$	7,390	$	9,547
	Accrued employee benefits			1,688		2,093
	Accrued warranty costs			8,118		6,651
	Accrued commissions			6,457		5,243
	Accrued income, value-added and sales taxes			5,730		3,319
	Accrued royalties			3,937		2,459
	Accrued other			9,106		7,642

			$	42,426	$	36,954

Other Noncurrent Liabilities	Other noncurrent liabilities consist of the following at December 31:


			2014		2013
			(In thousands)
	Noncurrent deferred rent		$	181	$	2
	Noncurrent deferred tax liability			1,347		8,673
	Noncurrent income tax reserve			—		51
	Noncurrent tenant improvement allowances			2,743		—
	License transfer agreement(1)			4,054		—

			$	8,325	$	8,726


	-1	On July 31, 2014, prior to Cynosure’s acquisition of Ellman, Ellman agreed to a binding license settlement with its previous owners. Ellman agreed to pay a future fixed payment commitment of $0.3 million in January 2015 and 2016 and $0.4 million each year from December 31, 2016 to December 31, 2028. Cynosure assumed this commitment, which is referred to as a license transfer agreement, as part of its purchase of substantially all of the assets of Ellman. The license transfer agreement was valued at $4.2 million as of the September 5, 2014 acquisition date using an interest rate of 4.75%. The current portion of $0.1 million is included within accrued expenses and the remainder of $4.1 million is classified as a component of other noncurrent liabilities within Cynosure’s December 31, 2014 consolidated balance sheet.

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
Stock-Based Compensation (Tables)	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Option Activity	Stock Options
	Stock option activity under the 2004 Plan and the 2005 Plan is as follows:


		Number of			Exercise Price		Weighted-		Weighted-		Aggregate
		Options			Range		Average		Average		Intrinsic
							Exercise		Remaining		Value
							Price		Contractual		(in thousands)
									Life
	Vested		1,596,565		$	3.00 - $36.94		16.93			$	16,061
	Unvested		707,301			9.56 - 28.68		23.06				2,985

	Outstanding, December 31, 2013		2,303,866		$	3.00 - $36.94	$	18.81		6.51 years	$	19,046
	Granted		854,180			18.94 - 31.22		27.5				1,234
	Exercised		(587,359	)		3.00 - 28.68		13.88				9,116
	Forfeited		(82,199	)		10.15 - 29.40		27.73				91

	Outstanding, December 31, 2014		2,488,488		$	4.50 - $36.94	$	22.66		6.78 years	$	13,713

	Vested		1,704,455			4.50 - 36.94		20.62		5.78 years		12,417
	Unvested		784,033			11.76 - 31.22		27.09		8.96 years		1,296

	Vested or expected to vest, December 31, 2014		2,451,983		$	4.50 - $36.94	$	22.58		6.75 years	$	13,670

	Exercisable, December 31, 2014		1,704,455		$	4.50 - $36.94	$	20.62		5.78 years	$	12,417
Summary of RSUs Activity under 2005 Plan	Restricted Stock Units
	RSU activity under the 2005 Plan is as follows:


		Number of			Grant Date Fair		Weighted-		Weighted-		Aggregate
		RSUs			Value		Average		Average		Intrinsic
					Range		Grant		Remaining		Value
							Date Fair		Contractual		(in thousands)
							Value		Life
	Outstanding, December 31, 2013		—		$	—	$	—		—	$	—
	Granted		88,340			21.11 - 29.40		25.32				2,422
	Exercised		(32,957	)		21.11 - 29.40		23.93				811
	Forfeited		—			—		—				—

	Outstanding, December 31, 2014		55,383		$	21.11 - $29.40	$	26.14		9.22 years	$	1,518

	Vested		—			—		—		—		—
	Unvested		55,383			21.11 - 29.40		26.14		9.22 years		1,518

	Vested or expected to vest, December 31, 2014		53,700		$	21.11 - $29.40	$	26.04		9.22 years	$	1,472

	Exercisable, December 31, 2014		—		$	—	$	—		—	$	—
Summary of RSU Grant and Unrecognized Compensation Expense	The following table summarizes the RSU grant and unrecognized compensation expense for the year ended December 2014.



		Number of RSUs			Unrecognized		Weighted
		Granted			Stock-based		Average Period
					Compensation at		for Recognition
					December 31,		of Unrecognized
					2014		Compensation
					(in thousands)
	As of December 31, 2014		88,340		$	1,278		1.3 years

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income (Loss) Before Income Tax (Benefit) Provision	Income (loss) before income tax (benefit) provision consists of the following:


		2014			2013			2012
		(In thousands)
	Domestic	$	15,424		$	(8,633	)	$	10,344
	Foreign		2,914			3,096			2,381

	Total	$	18,338		$	(5,537	)	$	12,725

(Benefit) Provision for Income Taxes	The (benefit) provision for income taxes consists of:


		2014			2013			2012
		(In thousands)
	Current:
	Federal	$	734		$	732		$	1,382
	State		577			214			128
	Foreign		1,306			890			606

	Total current		2,617			1,836			2,116
	Deferred:
	Federal		(13,032	)		(5,406	)		152
	State		(1,398	)		(304	)		—
	Foreign		(1,187	)		(16	)		(504	)

	Total deferred		(15,617	)		(5,726	)		(352	)

		$	(13,000	)	$	(3,890	)	$	1,764

Reconciliation of Federal Statutory Rate	A reconciliation of the federal statutory rate to Cynosure’s effective tax rate is as follows for the years ended December 31:


		2014			2013			2012
	Income tax provision at federal statutory rate:		35	%		35	%		35	%
	Increase (decrease) in tax resulting from -
	State taxes, net of federal benefit		0.8			(3.1	)		0.7
	Nondeductible expenses		7.2			(11.9	)		2.1
	Tax-exempt interest income		(0.2	)		0.5			(0.3	)
	Effect of foreign taxes		(0.6	)		2.7			(1.8	)
	Stock-based compensation		0.1			(0.1	)		(0.9	)
	Research and development credit		(2.7	)		25.8			—
	Change in uncertain tax positions		(0.3	)		4.8			2.5
	Change in valuation allowance		(108.8	)		162			(20.5	)
	Change in control payments		1.6			(128.8	)		—
	Transaction costs		—			(13.6	)		—
	Other		(3.0	)		(3.1	)		(2.9	)

	Effective income tax rate		(70.9	)%		70.2	%		13.9	%

Significant Components of Deferred Tax Assets and Liabilities	Significant components of Cynosure’s deferred tax assets and liabilities as of December 31, 2014 and 2013 are as follows:


		2014			2013
		(In thousands)
	Deferred tax assets:
	Accrued expenses and reserves	$	7,917		$	9,747
	Domestic net operating loss & tax credit carry-forwards		15,873			19,925
	Foreign net operating loss carry-forwards		2,011			2,022
	Stock-based compensation		6,829			6,020
	Capital leases		5,955			5,472
	Other deferred tax assets		2,368			1,636

	Gross deferred tax assets	$	40,953		$	44,822
	Valuation allowance		(977	)		(19,186	)

	Total deferred tax assets (after valuation allowance)	$	39,976		$	25,636
	Long-term deferred tax liabilities:
	Intangible assets	$	(15,358	)	$	(18,227	)
	Fixed assets		(7,135	)		(5,463	)
	Other deferred tax liabilities		(847	)		(534	)

	Total long-term deferred tax liabilities	$	(23,340	)	$	(24,224	)
	Net deferred tax assets	$	16,636		$	1,412

Changes in Gross Unrecognized Tax Benefits	The aggregate changes in gross unrecognized tax benefits during the years ended December 31, 2014, 2013 and 2012 were as follows (in thousands):


		2014			2013			2012
	Balance at beginning of year	$	1,701		$	586		$	—
	Increases for tax positions taken during current period		—			76			398
	Increases for tax positions taken in prior periods		—			—			188
	Increases for acquired tax positions taken in prior periods		—			1,625			—
	Decreases for acquired tax positions within measurement window		(815	)		—			—
	Decreases for tax positions taken in prior periods		(76	)		(398	)		—
	Decreases for lapse in statutes		—			(188	)		—

	Balance at end of year	$	810		$	1,701		$	586

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Operating Facility, Certain Equipment and Vehicles Under Operating Lease and Capital Lease Agreements with Payments	Cynosure leases the buildings portion of its U.S. operating facility and certain equipment and vehicles under capital lease agreements with payments due through May 2027. Commitments under Cynosure’s lease arrangements are as follows (in thousands):


		Operating		Capital
		Leases		Leases
	2015	$	2,073	$	164
	2016		1,966		2,194
	2017		1,948		2,572
	2018		1,895		2,520
	2019		1,411		2,514
	Thereafter		2,747		20,166

	Total minimum lease payments	$	12,040	$	30,130

	Less amount representing interest				(13,905	)

	Present value of obligations under capital leases			$	16,225
	Current portion of capital lease obligations				137

	Capital lease obligations, net of current portion			$	16,088

Summary_Selected_Quarterly_Fin1

Summary Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Unaudited Consolidated Quarterly Results of Operations	The results of operations for any quarter are not necessarily indicative of the results of operations for any future period.


			Quarter Ended
			March 31,		June 30,			Sept. 30,			Dec. 31,
			2014		2014			2014			2014
			(In thousands, except per share data)
	Revenues		$	62,004	$	72,573		$	71,530		$	86,262
	Gross profit		$	35,395	$	40,693		$	40,298		$	48,852
	Income from operations		$	1,346	$	6,398		$	5,250		$	8,266
	Net income(1)		$	689	$	4,575		$	3,074		$	23,000
	Basic net income per share(1)		$	0.03	$	0.21		$	0.14		$	1.06
	Diluted net income per share(1)		$	0.03	$	0.2		$	0.14		$	1.05

	-1	Net income and basic and diluted net income per share data for the quarter ended December 31, 2014 include an income tax benefit of $19.9 million resulting from the release of substantially all of the valuation allowance maintained against Cynosure’s net U.S. deferred tax asset.


			Quarter Ended
			March 31,		June 30,			Sept. 30,			Dec. 31,
			2013		2013			2013			2013
			(In thousands, except per share data)
	Revenues		$	40,690	$	50,091		$	60,692		$	74,537
	Gross profit		$	23,687	$	27,787		$	34,134		$	44,672
	Income (loss) from operations		$	1,988	$	(14,639	)	$	(1,426	)	$	8,250
	Net income (loss)		$	1,239	$	(8,954	)	$	(1,281	)	$	7,349
	Basic net income (loss) per share		$	0.08	$	(0.54	)	$	(0.06	)	$	0.33
	Diluted net income (loss) per share		$	0.07	$	(0.54	)	$	(0.06	)	$	0.33

Nature_of_the_Business_Additio

Nature of the Business - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2014
	Country
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of countries using international distributors	120
Date of incorporation	10-Jul-91

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	Customer	Customer	Customer
	Reporting_Unit	Reporting_Unit
Summary Of Significant Accounting Policies [Line Items]
Liquid investments with original maturities	90 days
Significant off-balance-sheet risk or concentration of credit risk, Description	Cynosure has no significant off-balance-sheet risk or concentration of credit risk, such as foreign exchange contracts, options contracts, or other foreign hedging arrangements.
Accounts receivable, net	$42,524,000	$36,587,000
Allowance for doubtful accounts receivable	2,949,000	1,803,000
Number of major customer revenue	0	0	0
Number of major customer accounts receivable	0	0
Laser transferred to fixed assets useful life	3 years
Long lived assets impairment	0
Goodwill impairment	0	0
Number of reporting unit	1	1
Shipping and handling billing earned	1,000,000	600,000	400,000
Shipping and handling cost	1,100,000	600,000	500,000
Standard product warranty period	1 year
Advertising costs	1,200,000	1,100,000	600,000
Foreign currency remeasurement (losses) gain	-1,600,000	300,000	400,000
Stock-based compensation expense	7,113,000	3,688,000	2,910,000
Stock-based compensation expense capitalized to inventory	23,000	23,000
Unrecognized compensation expense related to non-vested share awards	10,100,000
Share based compensation period	1 year 7 months 6 days
Cash received from option exercises	8,200,000	2,700,000	7,200,000
Stock options granted	854,180	617,510	405,790
Weighted average fair value of the options granted	$10.50	$10.25	$9.23
Cash dividend yield	0.00%
Stock option and RSU's excluded from computation of earning per share	500,000	1,300,000	700,000
Settlement Agreement [Member]
Summary Of Significant Accounting Policies [Line Items]
Amount to be received		10,000,000
Amount to be paid		2,000,000
Royalty revenue	3,000,000	4,000,000
Cost of royalty revenue	$800,000	$1,000,000
Common Stock Class B [Member]
Summary Of Significant Accounting Policies [Line Items]
Common Stock, shares outstanding	0	0	0
Restricted Stock Units (RSUs) [Member]
Summary Of Significant Accounting Policies [Line Items]
Share based compensation period	3 years
Granted restricted stock units to employees	44,840
Vested period	3 years
Restricted Stock Units (RSUs) [Member] \| Non Employee Director [Member]
Summary Of Significant Accounting Policies [Line Items]
Share based compensation period	1 year
Granted restricted stock units to employees	43,500
Vested period	1 year
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Laser held as inventory period	1 year
Intangible assets Amortization over the estimated useful lives	23 years
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Intangible assets Amortization over the estimated useful lives	5 years

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Accounts Receivable Allowance Activity (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]
Balance at beginning of year	$1,803	$2,043	$1,872
Additions	2,373	1,058	591
Deductions	-1,227	-1,298	-420
Balance at end of year	$2,949	$1,803	$2,043

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Inventories (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
Raw materials	$16,875	$16,900
Work in process	3,526	2,316
Finished goods	38,917	31,035
Inventories, Total	$59,318	$50,251

Summary_of_Significant_Account6

Summary of Significant Accounting Policies - Activity in the Accrued Warranty Account (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]
Balance at beginning of year	$6,651	$3,415	$3,171
Warranty provision related to new sales	15,104	9,114	4,641
Warranty provision assumed from acquisitions		1,422
Costs incurred	-13,637	-7,300	-4,397
Balance at end of year	$8,118	$6,651	$3,415

Summary_of_Significant_Account7

Summary of Significant Accounting Policies - Changes to Accumulated Other Comprehensive Loss (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]
Unrealized Gain on Marketable Securities, net of taxes, Beginning Balance	$36
Unrealized Gain on Marketable Securities, net of taxes, Current period other comprehensive loss	-46	23	-10
Unrealized Gain on Marketable Securities, net of taxes, Ending Balance	-10	36
Translation Adjustment, Beginning Balance	-1,535
Translation Adjustment, Current period other comprehensive loss	-2,318	77	452
Translation Adjustment, Ending Balance	-3,853	-1,535
Accumulated Other Comprehensive Loss, Beginning Balance	-1,499
Accumulated Other Comprehensive Loss, Current period other comprehensive loss	-2,364	100	442
Accumulated Other Comprehensive Loss, Ending Balance	($3,863)	($1,499)

Summary_of_Significant_Account8

Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Expenses (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$7,113	$3,688	$2,910
Cost of Revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	292	174	127
Sales and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	1,934	1,090	857
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	1,007	594	495
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation expense	$3,880	$1,830	$1,431

Summary_of_Significant_Account9

Summary of Significant Accounting Policies - Summary of Share-Based Compensation Arrangement Fair Value Assumptions (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used [Line Items]
Risk-free interest rate Minimum	1.41%	0.33%	0.61%
Risk-free interest rate Maximum	1.80%	1.49%	0.86%
Expected dividend yield	0.00%	0.00%	0.00%
Expected term	4 years 7 months 6 days		5 years 9 months 18 days
Expected volatility Minimum	43.00%	44.00%	56.00%
Expected volatility Maximum	44.00%	56.00%	57.00%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used [Line Items]
Expected term		2 years
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used [Line Items]
Expected term		4 years 9 months 18 days

Recovered_Sheet1

Summary of Significant Accounting Policies - Schedule of Reconciliation of Basic and Diluted Shares (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Abstract]
Net income (loss)	$23,000	$3,074	$4,575	$689	$7,349	($1,281)	($8,954)	$1,239	$31,338	($1,647)	$10,961
Basic weighted average common shares outstanding									21,824	19,325	13,189
Weighted average common stock equivalents									371		603
Diluted weighted average common shares outstanding									22,195	19,325	13,792
Basic net income (loss) per share	$1.06	$0.14	$0.21	$0.03	$0.33	($0.06)	($0.54)	$0.08	$1.44	($0.09)	$0.83
Diluted net income (loss) per share	$1.05	$0.14	$0.20	$0.03	$0.33	($0.06)	($0.54)	$0.07	$1.41	($0.09)	$0.79

Fair_Value_Measurement_of_Fair

Fair Value - Measurement of Fair Value Hierarchy for Financial Assets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial assets	$59,997	$41,415
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial assets	1,766	5,234
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial assets	58,231	36,181
State and Municipal Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial assets	47,744	18,133
State and Municipal Bonds [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial assets	47,744	18,133
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial assets	1,753	5,185
Money Market Funds [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial assets	1,753	5,185
Treasuries and Government Agencies [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial assets	8,486	15,028
Treasuries and Government Agencies [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial assets	8,486	15,028
Corporate Obligations and Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial assets	2,001	3,020
Corporate Obligations and Commercial Paper [Member] \| Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial assets	2,001	3,020
Equity Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial assets	13	49
Equity Securities [Member] \| Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of financial assets	$13	$49

Fair_Value_Measurement_of_Fair1

Fair Value - Measurement of Fair Value Hierarchy for Financial Assets (Parenthetical) (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$59,997	$41,415
State and Municipal Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	47,744	18,133
State and Municipal Bonds [Member] \| Cash and Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents		$800

Short_and_LongTerm_Marketable_2

Short and Long-Term Marketable Securities - Additional Information (Detail) (USD $)	Dec. 31, 2014
Investments, Debt and Equity Securities [Abstract]
Available for sale securities in debt	$58,200,000
Available for sale securities in equity	$13,000

Short_and_LongTerm_Marketable_3

Short and Long-Term Marketable Securities - Schedule of Marketable Securities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Schedule of Available-for-sale Securities [Line Items]
Market Value	$58,244	$36,230
Amortized Cost	58,273	36,176
Unrealized Gains	10	54
Unrealized Losses	-39
Total marketable securities	58,244	35,437
Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Market Value		793
Amortized Cost		793
Cash Equivalents [Member] \| State and Municipal Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Market Value		793
Amortized Cost		793
Short-Term Marketable Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Market Value	32,055	26,633
Amortized Cost	32,052	26,581
Unrealized Gains	8	52
Unrealized Losses	-5
Short-Term Marketable Securities [Member] \| Corporate Obligations and Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Market Value	2,001	1,004
Amortized Cost	2,001	1,004
Short-Term Marketable Securities [Member] \| State and Municipal Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Market Value	26,041	10,552
Amortized Cost	26,033	10,551
Unrealized Gains	8	1
Short-Term Marketable Securities [Member] \| Treasuries and Government Agencies [Member]
Schedule of Available-for-sale Securities [Line Items]
Market Value	4,000	15,028
Amortized Cost	4,000	15,018
Unrealized Gains		10
Short-Term Marketable Securities [Member] \| Equity Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Market Value	13	49
Amortized Cost	18	8
Unrealized Gains		41
Unrealized Losses	-5
Long-Term Marketable Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Market Value	26,189	8,804
Amortized Cost	26,221	8,802
Unrealized Gains	2	2
Unrealized Losses	-34
Long-Term Marketable Securities [Member] \| Corporate Obligations and Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Market Value		2,016
Amortized Cost		2,015
Unrealized Gains		1
Long-Term Marketable Securities [Member] \| State and Municipal Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Market Value	21,703	6,788
Amortized Cost	21,721	6,787
Unrealized Gains	2	1
Unrealized Losses	-20
Long-Term Marketable Securities [Member] \| Treasuries and Government Agencies [Member]
Schedule of Available-for-sale Securities [Line Items]
Market Value	4,486
Amortized Cost	4,500
Unrealized Losses	($14)

Short_and_LongTerm_Marketable_4

Short and Long-Term Marketable Securities - Schedule of Available-for-Sale Debt Securities Mature (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]
Total	$58,231
Less Than One Year	32,042
One to Five Years	26,189
More than Five Years	0
State and Municipal Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Total	47,744
Less Than One Year	26,041
One to Five Years	21,703
More than Five Years	0
Treasuries and Government Agencies [Member]
Schedule of Available-for-sale Securities [Line Items]
Total	8,486
Less Than One Year	4,000
One to Five Years	4,486
More than Five Years	0
Corporate Obligations and Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Total	2,001
Less Than One Year	2,001
More than Five Years	$0

Acquisition_Additional_Informa

Acquisition - Additional Information (Detail) (USD $)

3 Months Ended

12 Months Ended

4 Months Ended

9 Months Ended

0 Months Ended

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Sep. 30, 2014

Jun. 24, 2013

Sep. 05, 2014

Business Acquisition [Line Items]

Goodwill

$6,598,000

Revenues

86,262,000

71,530,000

72,573,000

62,004,000

74,537,000

60,692,000

50,091,000

40,690,000

292,369,000

226,010,000

153,493,000

Ellman International, Inc. [Member]

Business Acquisition [Line Items]

Cash consideration

13,200,000

Business acquisition effective date of acquisition

5-Sep-14

License transfer agreement purchase price

4,200,000

Goodwill

6,600,000

5,900,000

Decreased in inventory

700,000

Revenues

11,500,000

Amount associated with step up in fair value of finished goods inventory included in consolidated pro forma financial information

300,000

Acquisition related costs

700,000

Palomar Medical Technologies, Inc. [Member]

Business Acquisition [Line Items]

Business acquisition effective date of acquisition

24-Jun-13

Decreased in inventory

3,800,000

Increase in deferred tax liability

200,000

Increase in accounts payable

100,000

Decrease in accrued expenses

$23,000

Acquisition_Estimated_Fair_Val

Acquisition - Estimated Fair Value of Net Assets Acquired (Detail) (USD $)	0 Months Ended
In Thousands, unless otherwise specified	Sep. 05, 2014	Dec. 31, 2014	Dec. 31, 2013
Assets (liabilities) acquired:
Goodwill		$105,764	$99,237
Ellman International, Inc. [Member]
Business Acquisition [Line Items]
Cash paid	13,235
Total	13,235
Assets (liabilities) acquired:
Accounts receivable	2,147
Inventory	3,682
Prepaid and other assets	488
Fixed assets	612
Intangible assets	6,800
Goodwill	6,598
Accounts payable	-9
Accrued expenses	-2,469
Deferred revenue	-454
License transfer agreement	-4,160
Total	$13,235

Acquisition_Proforma_Condensed

Acquisition - Pro-forma Condensed Consolidated Operating Results (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Business Combinations [Abstract]
Revenue (unaudited)	$308,980	$255,077
Pre-tax income (loss) (unaudited)	$17,978	($12,261)

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets - Schedule of Changes to Goodwill (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Balance-December 31, 2013 (recast)	$99,237
Ellman acquisition	6,598
Translation adjustment	-71
Balance-December 31, 2014	$105,764

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets - Schedule of Components of Other Intangible Assets (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Cost	$69,070	$61,995
Translation adjustment	38	70
Accumulated amortization	-15,525	-6,886
Other intangible assets, net	53,583	55,179
Developed Technology and Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	29,240	27,510
Accumulated amortization	-7,840	-2,216
Other intangible assets, net	21,400	25,294
Business Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	384	384
Translation adjustment	34	40
Accumulated amortization	-252	-239
Other intangible assets, net	166	185
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	19,718	15,833
Translation adjustment	2	26
Accumulated amortization	-5,818	-3,662
Other intangible assets, net	13,902	12,197
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	18,390	16,930
Accumulated amortization	-1,607	-761
Other intangible assets, net	16,783	16,169
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	1,338	1,338
Translation adjustment	2	4
Accumulated amortization	-8	-8
Other intangible assets, net	$1,332	$1,334

Goodwill_and_Other_Intangible_4

Goodwill and Other Intangible Assets - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$8.60	$3.10	$1.90
Indefinite-life intangible assets	1.3
Ellman International, Inc. [Member]
Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets acquired	6.8
Period of amortized identifiable intangible assets	13 years
Amortization expense	0.1
Ellman International, Inc. [Member] \| Cost of Revenues [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense	0.1
Ellman International, Inc. [Member] \| Technology Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets acquired	1.7
Period of amortized identifiable intangible assets	7 years
Ellman International, Inc. [Member] \| Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets acquired	3.6
Ellman International, Inc. [Member] \| Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets acquired	$1.50
Ellman International, Inc. [Member] \| Customer Relationships And Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Period of amortized identifiable intangible assets	15 years

Goodwill_and_Other_Intangible_5

Goodwill and Other Intangible Assets - Schedule of Amortization Expenses on Intangible Assets (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
2015	$9,223
2016	8,434
2017	6,444
2018	4,928
2019	3,189
2020 and Thereafter	20,405
Total	$52,623

Segment_and_Geographic_Informa2

Segment and Geographic Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2014
	Country
	Segment
Segment Reporting [Abstract]
Number of operating segments	1
Number of individual countries with greater than 10% of total revenue, total assets or total long lived assets	0
Percentage of total revenue	10.00%

Segment_and_Geographic_Informa3

Segment and Geographic Information - Schedule of Total Revenue by Geographic Destination (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$86,262	$71,530	$72,573	$62,004	$74,537	$60,692	$50,091	$40,690	$292,369	$226,010	$153,493
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues									148,803	111,179	72,704
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues									50,513	39,529	28,808
Asia Pacific [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues									64,651	52,574	39,991
Other [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues									$28,402	$22,728	$11,990

Segment_and_Geographic_Informa4

Segment and Geographic Information - Schedule of Total Assets by Geographic Area (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]
Total assets	$457,724	$414,701
Operating Segments [Member] \| United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total assets	420,513	380,383
Operating Segments [Member] \| Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total assets	23,235	21,741
Operating Segments [Member] \| Asia Pacific [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total assets	19,182	16,437
Eliminations [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total assets	($5,206)	($3,860)

Segment_and_Geographic_Informa5

Segment and Geographic Information - Schedule of Long-Lived Assets by Geographic Area (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets,Property Plant and Equipment	$34,256	$26,445
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets,Property Plant and Equipment	30,912	24,004
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets,Property Plant and Equipment	1,656	1,326
Asia Pacific [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets,Property Plant and Equipment	$1,688	$1,115

Balance_Sheet_Accounts_Propert

Balance Sheet Accounts - Property and Equipment (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$65,788	$58,054
Less: Accumulated depreciation and amortization	-31,532	-31,609
Property and Equipment, Net	34,256	26,445
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	9,834	7,835
Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	3,008	2,698
Furniture and Fixtures [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Furniture and Fixtures [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Property, Plant and Equipment, Gross	5,095	5,047
Leased Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	1,625	1,660
Leased Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Leased Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	4 years
Leased Buildings [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	14 years
Property, Plant and Equipment, Gross	13,327	13,327
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Property, Plant and Equipment, Gross	12,611	2,898
Demonstration Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Property, Plant and Equipment, Gross	20,246	24,094
Construction in-Progress [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$42	$495

Balance_Sheet_Accounts_Additio

Balance Sheet Accounts - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Balance Sheet Related Disclosures [Abstract]
Depreciation expenses	$8.90	$6	$5
Cost of assets recorded under capitalized leases	15	15
Related accumulated amortization	$2.40	$1.20

Balance_Sheet_Accounts_Accrued

Balance Sheet Accounts - Accrued Expenses (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Balance Sheet Related Disclosures [Abstract]
Accrued payroll and payroll taxes	$7,390	$9,547
Accrued employee benefits	1,688	2,093
Accrued warranty costs	8,118	6,651
Accrued commissions	6,457	5,243
Accrued income, value-added and sales taxes	5,730	3,319
Accrued royalties	3,937	2,459
Accrued other	9,106	7,642
Accrued Expenses, Total	$42,426	$36,954

Balance_Sheet_Accounts_Other_N

Balance Sheet Accounts - Other Noncurrent Liabilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Balance Sheet Related Disclosures [Abstract]
Noncurrent deferred rent	$181	$2
Noncurrent deferred tax liability	1,347	8,673
Noncurrent income tax reserve		51
Noncurrent tenant improvement allowances	2,743
License transfer agreement	4,054
Total other noncurrent liabilities	$8,325	$8,726

Balance_Sheet_Accounts_Other_N1

Balance Sheet Accounts - Other Noncurrent Liabilities (Parenthetical) (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Sep. 05, 2014	Dec. 31, 2013
Other Non Current Liabilities [Line Items]
Accrued expenses, current	$42,426,000		36,954,000
Ellman International, Inc. [Member]
Other Non Current Liabilities [Line Items]
Future fixed license commitment payment amount, 2015	300,000
Future fixed payment license commitment, expiration date	31-Dec-28
Future fixed license commitment payment amount, 2016	300,000
Future fixed license commitment payment amount, thereafter	400,000
License transfer agreement		4,160,000
Business acquisition effective date of acquisition	5-Sep-14
Accrued expenses, current	100,000
Other noncurrent liabilities	$4,100,000
Interest rate on present value of the financial commitment			4.75%

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Apr. 30, 2014	Dec. 31, 2013	Oct. 29, 2013
Schedule Of Equity [Line Items]
Common stock, par value	$0.00
Class A and Class B common stock, shares authorized	70,000,000		70,000,000
Preferred stock, par value	$0.00		$0.00
Preferred stock, shares authorized	5,000,000		5,000,000
Common Stock Class A [Member]
Schedule Of Equity [Line Items]
Common stock, par value	$0.00		$0.00
Class A and Class B common stock, shares authorized	61,500,000
Common stock, shares issued	23,253,000		22,633,000
Number of shares authorized to be repurchased		$35,000,000		$25,000,000
Increase in shares authorized to be repurchased		10,000,000
Treasury stock repurchased	742,179
Weighted average per share price of treasury stock	$20.96
Treasury stock acquired aggregate cost	15,600,000
Aggregate treasury stock repurchased	1,395,480
Treasury stock acquired aggregate cost	30,900,000
Shares available for repurchase	$4,100,000
Stock repurchase authorization description	On October 29, 2013, Cynosure announced that its board of directors authorized the repurchase of up to $25 million of its Class A common stock, from time to time, on the open market or in privately negotiated transactions under a stock repurchase program. On April 30, 2014, Cynosure's board of directors approved an increase of $10 million to the stock repurchase program. The program will terminate upon the purchase of $35 million in common stock or expiration of the program on November 1, 2015.
Expiration date of program	1-Nov-15
Common Stock Class B [Member]
Schedule Of Equity [Line Items]
Common stock, par value	$0.00		$0.00
Class A and Class B common stock, shares authorized	8,500,000
Common stock, shares issued	0		0

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail)	3 Months Ended				12 Months Ended
Stock-Based Compensation - Additional Information (Detail)	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2014
2004 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation fair market value percentage					110.00%
Stock based compensation voting stock percentage					10.00%
Stock option exceed in year					10 years
Option granted period					48 months
Stock option plan vested in percentage	6.25%	6.25%	6.25%	6.25%	25.00%
Shares available for future grant	0				0
2005 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation fair market value percentage					110.00%
Stock based compensation voting stock percentage					10.00%
Stock option exceed in year					10 years
Option granted period					36 months
Stock option plan vested in percentage	8.33%	8.33%	8.33%	8.33%
2005 Stock Incentive Plan [Member] \| Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option granted period					36 months
Stock option plan vested in percentage					33.00%
2005 Stock Incentive Plan [Member] \| Non Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option granted period					12 months
Stock option plan vested in percentage	25.00%	25.00%	25.00%	25.00%
2005 Stock Incentive Plan [Member] \| Common Stock Class A [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grant	1,417,338				1,417,338
Common stock shares reserved for future issuance under stock based plan	5,588,369				5,588,369

StockBased_Compensation_Stock_

Stock-Based Compensation - Stock Option Activity (Detail) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Granted, Number of Options	854,180
Exercised, Number of Options	-587,359
Forfeited, Number of Options	-82,199
Outstanding, Number of Options, Beginning Balance		2,303,866
Outstanding, Weighted-Average Exercise Price, Beginning balance		$18.81
Outstanding, Aggregate Intrinsic Value, Beginning balance		$19,046
Outstanding, Number of Options, Ending balance	2,488,488
Vested, Number of Options	1,704,455	1,596,565
Unvested, Number of Options	784,033	707,301
Vested or expected to vest, Number of Options	2,451,983
Exercisable, Number of Options	1,704,455
Granted, Exercise Price Range, Lower Limit	$18.94
Exercise, Exercise Price Range, Lower Limit	$3
Forfeited, Exercise Price Range, Lower Limit	$10.15
Outstanding, Exercise Price Range, Lower Limit Beginning Balance	$4.50	$3
Vested, Exercise Price Range, Lower Limit	$4.50	$3
Unvested, Exercise Price Range, Lower Limit	$11.76	$9.56
Vested or expected to vest, Exercise Price Range, Lower Limit	$4.50
Exercisable, Exercise Price Range, Lower Limit	$4.50
Granted, Exercise Price Range, Upper Limit	$31.22
Exercised, Exercise Price Range, Upper Limit	$28.68
Forfeited, Exercise Price Range, Upper Limit	$29.40
Outstanding, Exercise Price Range, Upper Limit Beginning Balance	$36.94	$36.94
Vested, Exercise Price Range, Upper Limit	$36.94	$36.94
Unvested, Exercise Price Range, Upper Limit	$31.22	$28.68
Vested or expected to vest, Exercise Price Range, Upper Limit	$36.94
Exercisable, Exercise Price Range, Upper Limit	$36.94
Granted, Weighted-Average Exercise Price	$27.50
Exercise, Weighted-Average Exercise Price	$13.88
Forfeited, Weighted-Average Exercise Price	$27.73
Outstanding, Weighted-Average Exercise Price, Ending balance	$22.66
Vested, Weighted-Average Exercise Price	$20.62	$16.93
Unvested, Weighted-Average Exercise Price	$27.09	$23.06
Vested or expected to vest, Weighted-Average Exercise Price	$22.58
Exercisable, Weighted average exercise price	$20.62
Outstanding Weighted-Average Remaining Contractual Life, Beginning balance	6 years 9 months 11 days	6 years 2 months 16 days
Vested, Weighted-Average Remaining Contractual Life	5 years 9 months 11 days
Unvested, Weighted-Average Remaining Contractual Life	8 years 11 months 16 days
Vested or expected to vest, Weighted-Average Remaining Contractual Life	6 years 9 months
Exercisable, Weighted-Average Remaining Contractual Life	5 years 9 months 11 days
Granted, Aggregate Intrinsic Value	1,234
Exercise, Aggregate Intrinsic Value	9,116
Forfeited, Aggregate Intrinsic Value	91
Outstanding, Aggregate Intrinsic Value, Ending balance	13,713
Vested, Aggregate Intrinsic Value	12,417	16,061
Unvested, Aggregate Intrinsic value	1,296	2,985
Vested or expected to vest, Aggregate Intrinsic value	13,670
Exercisable, Aggregate Intrinsic Value	$12,417

StockBased_Compensation_Summar

Stock-Based Compensation - Summary of RSUs Activity under 2005 Plan (Detail) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, Grant Date Fair Value Range, Upper Limit	$31.22
RSUs activity under the 2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted, Number of RSU's	88,340
Exercised, Number of RSU's	-32,957
Forfeited, Number of RSU's	0
Outstanding, Number of RSU's, Ending balance	55,383
Vested, Number of RSU's	0
Unvested, Number of RSU's	55,383
Vested or expected to vest, Number of RSU's	53,700
Exercisable, Number of RSU's	0
Granted, Grant Date Fair Value Range, Lower Limit	$21.11
Exercised, Grant Date Fair Value Range, Lower Limit	$21.11
Forfeited, Grant Date Fair Value Range, Lower Limit	$0
Outstanding, Grant Date Fair Value Range, Ending Balance, Lower Limit	$21.11
Vested, Grant Date Fair Value Range, Lower Limit	$0
Unvested, Grant Date Fair Value Range, Lower Limit	$21.11
Vested or expected to vest, Grant Date Fair Value Range, Lower Limit	$21.11
Exercisable, Grant Date Fair Value Range, Lower Limit	$0
Granted, Grant Date Fair Value Range, Upper Limit	$29.40
Exercised, Grant Date Fair Value Range, Upper Limit	$29.40
Forfeited, Grant Date Fair Value Range, Upper Limit	$0
Outstanding, Grant Date Fair Value Range, Ending Balance, Upper Limit	$29.40
Vested, Grant Date Fair Value Range, Upper Limit	$0
Unvested, Grant Date Fair Value Range, Upper Limit	$29.40
Exercisable, Grant Date Fair Value Range, Upper Limit	$0
Beginning balance, outstanding, weighted average grant date fair value	$26.14
Granted, weighted average grant date fair value	$25.32
Exercised, weighted average grant date fair value	$23.93
Forfeited, weighted average grant date fair value	$0
Vested, weighted average grant date fair value	$0
Unvested, weighted average grant date fair value	$26.14
Vested or expected to vest, weighted average grant date fair value	$26.04
Exercisable, weighted average grant date fair value	$0
Weighted average remaining contractual life, outstanding	9 years 2 months 19 days
Weighted average remaining contractual life, unvested	9 years 2 months 19 days
Weighted average remaining contractual life, vested or expected to vest	9 years 2 months 19 days
Aggregate intrinsic Value,Granted	$2,422
Aggregate intrinsic Value,Exercised	811
Forfeited , weighted average remaining contractual life	0
Aggregate intrinsic Value,Ending balance	1,518
Aggregate intrinsic Value,Vested	0
Aggregate intrinsic Value,Unvested	1,518
Vested or expected to vest , weighted average remaining contractual life	1,472
Aggregate intrinsic Value,Exercisable	$0

StockBased_Compensation_Summar1

Stock-Based Compensation - Summary of RSU Grant and Unrecognized Compensation Expense (Detail) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Weighted Average Exercise Price, and Additional Disclosures [Abstract]
Number of RSUs Granted	88,340
Unrecognized Stock- based compensation	$1,278
Weighted Average period for Recognition of unrecognized compensation	1 year 3 months 18 days

Income_Taxes_Loss_Income_befor

Income Taxes - (Loss) Income before Income Tax (Benefit) Provision (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Domestic	$15,424	($8,633)	$10,344
Foreign	2,914	3,096	2,381
Income (loss) before (benefit) provision for income taxes	$18,338	($5,537)	$12,725

Income_Taxes_Benefit_Provision

Income Taxes - (Benefit) Provision for Income Taxes (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current:
Federal	$734	$732	$1,382
State	577	214	128
Foreign	1,306	890	606
Total current	2,617	1,836	2,116
Deferred:
Federal	-13,032	-5,406	152
State	-1,398	-304
Foreign	-1,187	-16	-504
Total deferred	-15,617	-5,726	-352
Income tax expense (benefits)	($13,000)	($3,890)	$1,764

Income_Taxes_Reconciliation_of

Income Taxes - Reconciliation of Federal Statutory Rate (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Income tax provision at federal statutory rate:	35.00%	35.00%	35.00%
Increase (decrease) in tax resulting from -
State taxes, net of federal benefit	0.80%	-3.10%	0.70%
Nondeductible expenses	7.20%	-11.90%	2.10%
Tax-exempt interest income	-0.20%	0.50%	-0.30%
Effect of foreign taxes	-0.60%	2.70%	-1.80%
Stock-based compensation	0.10%	-0.10%	-0.90%
Research and development credit	-2.70%	25.80%
Change in uncertain tax positions	-0.30%	4.80%	2.50%
Change in valuation allowance	-108.80%	162.00%	-20.50%
Change in control payments	1.60%	-128.80%
Transaction costs		-13.60%
Other	-3.00%	-3.10%	-2.90%
Effective income tax rate	-70.90%	70.20%	13.90%

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
Income Taxes - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Deferred Tax Assets And Liabilities Classification [Line Items]
(Benefit) provision for income taxes	($13,000,000)	($3,890,000)	$1,764,000
Effective tax rate	-70.90%	70.20%	13.90%
Unrecognized tax benefit resulting from acquisition	19.9
Unrecognized tax benefits	810,000	1,701,000	586,000
Cumulative income postion period	3 years
Undistributed earnings of foreign subsidiaries	14,000,000
Unrecognized tax benefit if recognized would impact effective tax rate	810,000	100,000	300,000
Non-U.S. jurisdictions [Member]
Deferred Tax Assets And Liabilities Classification [Line Items]
Net operating loss carry-forward	6,000,000
Differences between the statutory tax rate and effective tax rate [Member]
Deferred Tax Assets And Liabilities Classification [Line Items]
Unrecognized tax benefits	6,900,000
United States [Member]
Deferred Tax Assets And Liabilities Classification [Line Items]
Net operating loss carry-forward	29,800,000
Tax credit carry-forwards	6,900,000
Net operating loss carry-forwards, expiration start year	2021
Tax credits, expiration start year	2018
U.S. state tax [Member]
Deferred Tax Assets And Liabilities Classification [Line Items]
Net operating loss carry-forward	500,000
Tax credit carry-forwards	2,100,000
Net operating loss carry-forwards, expiration start year	2018
Tax credits, expiration start year	2016
Japan [Member] \| Non-U.S. jurisdictions [Member]
Deferred Tax Assets And Liabilities Classification [Line Items]
Net operating loss carry-forwards, expiration start year	2019
Mexican [Member] \| Non-U.S. jurisdictions [Member]
Deferred Tax Assets And Liabilities Classification [Line Items]
Net operating loss carry-forwards, expiration start year	2019
Spain [Member] \| Non-U.S. jurisdictions [Member]
Deferred Tax Assets And Liabilities Classification [Line Items]
Net operating loss carry-forwards, expiration start year	2029
Palomar Medical Technologies, Inc. [Member]
Deferred Tax Assets And Liabilities Classification [Line Items]
Unrecognized tax benefit resulting from acquisition	19,000,000
Decrease in income tax valuation allowance	18,200,000
Palomar Medical Technologies, Inc. [Member] \| Cynosure Japan Palomar Australia And Palomar Spain [Member]
Deferred Tax Assets And Liabilities Classification [Line Items]
Decrease in income tax valuation allowance	900,000
Palomar Medical Technologies, Inc. [Member] \| Cynosure Japan Palomar Australia And Palomar Spain [Member] \| Differences between the statutory tax rate and effective tax rate [Member]
Deferred Tax Assets And Liabilities Classification [Line Items]
Unrecognized tax benefit resulting from acquisition	900,000
Palomar Medical Technologies, Inc. [Member] \| Stock Based Compensation Tax Benefit [Member] \| United States [Member]
Deferred Tax Assets And Liabilities Classification [Line Items]
Net operating loss carry-forward	0
Tax credit carry-forwards	2,000,000
Palomar Medical Technologies, Inc. [Member] \| Stock Based Compensation Tax Benefit [Member] \| U.S. state tax [Member]
Deferred Tax Assets And Liabilities Classification [Line Items]
Net operating loss carry-forward	200,000
Tax credit carry-forwards	100,000
Valuation Allowance of Deferred Tax Assets [Member] \| Palomar Medical Technologies, Inc. [Member]
Deferred Tax Assets And Liabilities Classification [Line Items]
Decrease in income tax valuation allowance	$19,000,000

Income_Taxes_Significant_Compo

Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Accrued expenses and reserves	$7,917	$9,747
Domestic net operating loss & tax credit carry-forwards	15,873	19,925
Foreign net operating loss carry-forwards	2,011	2,022
Stock-based compensation	6,829	6,020
Capital leases	5,955	5,472
Other deferred tax assets	2,368	1,636
Gross deferred tax assets	40,953	44,822
Valuation allowance	-977	-19,186
Total deferred tax assets (after valuation allowance)	39,976	25,636
Long-term deferred tax liabilities:
Intangible assets	-15,358	-18,227
Fixed assets	-7,135	-5,463
Other deferred tax liabilities	-847	-534
Total long-term deferred tax liabilities	-23,340	-24,224
Net deferred tax assets	$16,636	$1,412

Income_Taxes_Changes_in_Gross_

Income Taxes - Changes in Gross Unrecognized Tax Benefits (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at beginning of year	$1,701	$586
Increases for tax positions taken during current period		76	398
Increases for tax positions taken in prior periods			188
Increases for acquired tax positions taken in prior periods		1,625
Decreases for acquired tax positions within measurement window	-815
Decreases for tax positions taken in prior periods	-76	-398
Decreases for lapse in statutes		-188
Balance at end of year	$810	$1,701	$586

401k_Plans_Additional_Informat

401(k) Plans - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Schedule Of Sale Of Subsidiary [Abstract]
Total contributions to this plan	$0.90	$0.60	$0.40

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Commitments and Contingencies Disclosure [Abstract]
Operating lease rent expense	$3.20	$2.40	$2.10
Operating lease expiration period			2027-05

Commitments_and_Contingencies_2

Commitments and Contingencies - Operating Facility, Certain Equipment and Vehicles Under Operating Lease and Capital Lease Agreements with Payments (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
2015	$2,073
2016	1,966
2017	1,948
2018	1,895
2019	1,411
Thereafter	2,747
Total minimum lease payments	12,040
2015	164
2016	2,194
2017	2,572
2018	2,520
2019	2,514
Thereafter	20,166
Total minimum lease payments	30,130
Less amount representing interest	-13,905
Present value of obligations under capital leases	16,225
Current portion of capital lease obligations	137	286
Capital lease obligations, net of current portion	$16,088	$14,957

Summary_Selected_Quarterly_Fin2

Summary Selected Quarterly Financial Data (Unaudited) - Unaudited Consolidated Quarterly Results of Operations (Detail) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Revenues	$86,262	$71,530	$72,573	$62,004	$74,537	$60,692	$50,091	$40,690	$292,369	$226,010	$153,493
Gross profit	48,852	40,298	40,693	35,395	44,672	34,134	27,787	23,687	165,238	130,280	88,926
Income (loss) from operations	8,266	5,250	6,398	1,346	8,250	-1,426	-14,639	1,988	21,260	-5,827	12,133
Net income (loss)	$23,000	$3,074	$4,575	$689	$7,349	($1,281)	($8,954)	$1,239	$31,338	($1,647)	$10,961
Basic net income (loss) per share	$1.06	$0.14	$0.21	$0.03	$0.33	($0.06)	($0.54)	$0.08	$1.44	($0.09)	$0.83
Diluted net income (loss) per share	$1.05	$0.14	$0.20	$0.03	$0.33	($0.06)	($0.54)	$0.07	$1.41	($0.09)	$0.79

Summary_Selected_Quarterly_Fin3

Summary Selected Quarterly Financial Data (Unaudited) - Unaudited Consolidated Quarterly Results of Operations (Parenthetical) (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Unrecognized tax benefit resulting from acquisition	$19.90